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Abstract of Thesis
Since the time of thE: introduction of the SJ:)!Jntaneously hypertensive rat (SHR) into medical researchJ sev-eral neuropharmacological studies have been performed on these animals whi.ch
have been unrelated to their cardiovascular systems. A few of
these studies have indicated possible abnormalities in the dopaminergi.c systems of' SHR. 'rherefore the pres~ent study was undertaken to examine more closely the sensi.ti\•'ity of SI-l:H to
stimulat:i.on of their dopamine ( DA) receptors.
Three rat strains were utilized in this study: 1) SHR; 2) Wistar-Kyoto rat ( WKY); and .}) lftJistar rat ( Nli'IR)', --Three parameters were chosen on the basis of' their a1)pearance after
stimulation of DA receptors in three different brain regions:
1) stereotyped behavior via stimulation of DA receptors in the
corpus striatum; .f.) locomotor activity via stimulation of DA
receptors in the mesoli.mbic forebrain; and ]J hypothermia via
stimulation of DA receptors in the hypothalamus. Apomorphine
(APO) was chosen as the DA agonist.
No significant difference in APO-induced stereotyped behavior
was found to exist between the three rat strains suggesting
that there is no alteration in the sensitivity of DA receptors
in the corpus striatum of SHR.
'--

No significant difference was found to exist between the three
rat strains with respect to either spontaneous locomotor activity or APO-induced locomotor activity suggesting that there is
no alteration in the sensitivity of DA receptors in the mesolimbic forebrain of SHR.
SHR was found to be more sensitive than 11WR te the hypothermic

effect of APO. F'rom parallel log-dose respon.se curves of the
three rat strains, APO and a second DA agonist, L-DOPA, were
calculatEld to be more potent in producing hy])o"thermia in SHR
than Nt'IIR. WKY showed a hypothermic response intermediate to
SHR and NWR. NV.JR and WKY were more susceptit:he than SHR to
antagonism of APO-induced hypothermia by haloperidol. Chronic
lithium treatment had no effect on APO-induced: hypothermia in
NWR and WKY. Lithium was found to significantly attenuate APOinduced hypothermia in SHR and to alter this. response to one
similar to those shown by NWR and Vvl\:Y. Chrom.•ic hydralazine
treatment in SHR had no effect on APO-inducedl. hypotht~rmia.
Since lithium has the ability to "stabilize•~ supersensitive DA
receptors, and APO -induced hypothermia in SHR:, it is prot)Qsed
that DA receptors in the hypothalamus responsible for mediating
hypothermia arc supersensitive in SHR.

viii
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INTRODUCTION
A.

Spontaneously Hypertensive Rat
Development of a genetically pure strain of rat in which

there occurs 100 perc•9nt spontaneous hypertension was reported in 1963 by Okamoto and Aoki.

These investigators

isolated this strain by mating a male Wistar rat showing
spontaneous hypertension to a female of the same strain displaying a blood pressure slightly above average.

This mating

produced F 1 rats. F 2 rats were obtained from brother-sister
matings of F 1 rats which had been selected for their persistent hypertension.

Pairs of F 2 rats which showed persistent
hypertension were then selected for brother-sister matings to
obtain FJ rats.

This procedure of matings was carried on to

the sixth generation of offspring.

It was noted that the

incidence of occurrence of spontaneous hypertension and the
development of hypertension occurred at younger ages from
generation to generation so that by the third generation all
rats developed spontaneous hypertension within fifteen weeks
of age.

Since the incidence of occurrence of spontaneous

. hypertension was 100 percent, these researchers suggested
that this strain of Wistar rat be named "spontaneously hypertensive rat (Okamoto and Aoki)" (Okamoto and Aoki, 196J).
1

2

Being that this research was carried on at the Kyoto University in Japan, this particular colony of Wistar rat strain·
from which the spontaneously hypertensive rat was isolated
became known as Wistar-:-Kyoto.
As an increased sympathetic tone quite often corresponds
with hypertension, and may possibly be the cause in the spontaneously hypertensive rat (SHR), many investigations have
tried to determine

s~~pathetic

activity in SHR.

Earlier

studies, utilizing biochemical techniques, showed a decreased
norepinephrine (NE) turnover in cardiac tissue of SHR.

Since

NE uptake and endogenous levels were found to be the same in
SHR as in the control rat strain, it was concluded that there
is a decreased release of NE from heart tissue (Louis et al.,
1968; Sjoerdsma, 1972).

Further studies on this organ

indicated a reduced rate of synthesis of NE in SHR.

These

differences could not be attributed to differences in endogenous levels of NE since these levels were the same in both
strains (Louis et al., 1969, 1970; Sjoerdsma, 1972).

Naka-

mura et al. (1971) confirmed the reduction in cardiac turnover in SHR but found that the endogenous levels were significantly lower.

Furthermore, these researchers found that the

higher the blood .pressure the slower the NE turnover.

These

results led to the conclusion that the decrease in peripheral
NE turnover represents a decrease in sympathetic nerve activity.

This decrease 'in sympathetic activity was suggested to

be an attempt to compensate for an increased peripheral vascular resistance.
In contrast to the biochemical evidence of a decrease in

3
sympathetic nerve activity in SHR, an increasing amount of
literature suggestsan augmented sympathetic tone.

Okamoto

and coworkers (1967) found that the discharge rate of the
left splanchnic nerve of SHR was significantly greater than
that of control Wistar rat.

Application of square pulses

(Iriuchijima, 1973) of voltage to the peripheral cut ends of
the left or right splanchnic nerve indicated that the number of stimulations, or frequency, required to restore arterial pressure to thB level prior to nerve severance was
significantly greater in SHR than control Wistar rat.

Assum-

ing that this frequency represents the average discharge rate
of the sympathetic vasoconstrictor fibers in the splanchnic
nerye, it appears that SHR has a significantly greater discharge rate.
Direct measurements of sympathetic nerve activity had
shown that there is a two- to three-fold increase in sympathetic activity in SHR.

This increase in sympathetic activity

was shown to be generalized to the nerves supplying the abdominal viscera and cervical·sympathetic chain.

A high correla-

tion was found between the age of SHR and their corresponding
sympathetic nerve activity.

Blockade of sympathetic ganglia

with hexamethonium lowered the blood pressure to identical
levels in SHR and Wistar rat (Judy et al., 1976).
Inhibition of sympathetic nerve activity by reflex
mechanisms indicated that the pressure-sensitive baroreceptors
were not able to inhibit sympathetic nerve activity as effectively in SHR as in normotensive Wistar rat when stimulated
by rises in systemic arterial pressure of equal magnitude and

4
duration (Judy et

al~,

1976; Coote and Sato, 1977).

This

reduction in effectiveness of the baroreceptors to completely .
inhibit sympathetic nerve activity decreases as a function of
age (Judy et al.,· 19'76).

A high sympathetic activity in SHR

has been suggested a.s the reason for the reduction in ability
of the cardiovascular pressure receptors to inhibit ongoing
sympathetic activity.

In other words, the excitatory drive

onto sympathetic neurons can better overcome baroreceptor
inhibition in SHR than in Wistar rat.

It was hypothesized

that there is throughout life a continual imbalance in the
pressure-receptor-sympathetic neuron control system which cannot be counteracted.

This imbalance was suggested to be a

consequence of increased sympathetic·activity {Coote and Sato,

1977).

Transection experiments by Okamoto et al. (1967) indi-

cated that the increased sympathetic vasoconstrictor activity
may originate in the ponte-bulbar portion of the brainstem.
Since baroreceptor sinus reflex appears to be less effective in inhibiting sympathetic nerve activity in SHR, alterations in baroreceptor function had been suggested as a causative factor for the hypertension.

Nosaka and Wang (1972)

found that the thr:.eshold pressure required for the carotid
sinus to elicit hypotensive responses was significantly higher
in SHR than in normotensive Wistar rat.

Pressures required

to stimulate maximum hypotensive responses were also significantly higher.

These results indicate that baroreceptor sen-

sitivity, at least of the carotid sinus, in SHR is shifted
towards operating at higher pressures.

No alterations in

sensitivity of the baroreceptor response to changes in pressure

.5
occur with this resetting.

Similar results were found for

the aortic sinus (Sapru and Wang, 1976).

Additionally, it

was found that resetting of the baroreceptors could be prevented by antihypertensive therapy of 11-week old SHR.

Treat-

ment of older SHR resulted in reversal of resetting in some
but not all animals.

Histological examination of vessel

walls revealed that reversal or prevention of aortic hypertrophy correlated with reversal or prevention of baroreceptor
resetting whereas partial reversal of baroreceptor resetting
occurred with partial reversal of hypertrophy.

It was sug-

gested that high sympathetic tone results in irreversible
hypertrophy of the tunica media of the vessel walls.

This

thickening of the aorta causes a resetting of the baroreceptors at a higher pressure level without altering the normal·
sensitivity of the baroreceptor.
Nakamura and Nakamura (1977) reported that an enhanced
sympathetic activity in young SHR is not responsible for the
development of hypertension.

These investigators noted that

young-pre-hypertensive SHR have elevated activities of choline acetyltransferase and tyrosine hydroxylase (TH) in the
celiac ganglia as compared to Wistar-Kyoto rat strain.

Ele-

vated activities of these enzymes were not found in the superior cervical ganglia, stellate ganglia or adrenal glands.
This rise in activity of both enzymes in the celiac ganglia
disappeared in the adult SHR.

Bilateral removal of the celiac

ganglion did not alter the development of hypertension.
was suggested that the faster maturation of the celiac
ganglion in SHR is causally related to activation of the

It
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peripheral sympathetic nervous system.

Therefore, it was

concluded that peripheral sympathetiq activation in young
SHR be regarded as a warning sign, but that this activation
does not trigger the development of hypertension.
In contrast to Nakamura and Nakamura (1977), Vapaatalo
et al. (1974) found that 6-hydroxydopamine (6-0HDA) given to
newborn SHR prevented the development of hypertension.

Since

6-0HDA is known to de:stroy peripheral and central adrenergic
nerve terminals

(Mal~fors

and Sachs, 1968; Thoenen and Tran-

zer, . 1968; Tranzer and Thoenen, 1968; Bloom et al. , 1969;
Uretsky and Iversen, :l969, 1970), it was concluded that the
sympathetic nervous system and/or adrenergic structures play
an important part in the development of hypertension in SHR.
It appears that interference with either of these systems
shortly after birth can prevent the development of the biochemical and/or histopathological changes·responsible for the
development and/or maintenance of spontaneous hypertension.
This interference could be due to either central or perip.heral
mechanisms.

It may be a central mechanism as it had pre-

viously been shown (Haeusler et al., 1972) that administration
of 6-0HDA into the lateral brain ventricle of ?-week old SHR
prevented the development of hypertension.

Furthermore, the

dose-response curves of vascular reactivity to NE of animals
that developed hypertension were steeper and displayed a
higher maximum whereas the dose-response curves of SHR treated
with

6~0HDA

controls.

were virtually identical to those of normotensive
It was proposed that there is a central trigger

mechanism for the development of hypertension.

7
The search for a central trigger mechanism has centered
on central catecholan1ine levels, catecholamine turnover, and
enzyme activities.

Early studies indicated a decreased NE

synthesis in the brainstem of SHR whereas the endogenous
levels were similar between SHR and Wistar rat (Louis et al.,
1970).

Nakamura et al. (1971) found that NE levels in the

hypothalamus and medl.Jlla-pons of 6- and 12-week old. SHR were
the same as Wistar rat.

Wistar-Kyoto rat was later found to

also have similar NE contents in these brain regions (De
Jong et al., 1975).

No change in NE content or turnover was

found to exist in the! brainstem of SHR in relation to changes
in blood pressure (Nakamura et al., 1971).

Yamori and co-

workers (1971) found that the NE content of the brainstem and
hypothalamus was significantly lower in SHR than in Wistar rat.
It was noted in 6-week old SHR that DOPA decarboxylase
activity was 50 percent of that of Wistar rat.

This reduction

in activity was not attributed to depression secondary to the
increased blood pressure (Yamori et al., 1970; Nagatsu et al.,
1972).

Other studies also revealed a lower NE content and a

slower rate of synthesis in the brainstem of SHR than Wistar
rat (Sjoerdsma, 1972).

However, Wistar-Kyoto rat (when this

strain became available for study) was found to have a NE
content similar to that of SHR (Yamabe et al., 197.3; Osumi et
al., 1974).

Similar results were found with respect to NE

turnover when SHR were compared to Wistar-Kyoto rat.

Enzyme

studies showed that Wistar rat had significantly higher levels
of activity of TH, DOPA decarboxylase, and dopamine-betahydroxylase (DBH) than either SHR or Wistar-Kyoto rat.

It

-------~-------~~-
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appears that the variations in catecholamine levels, catecholamine turnover, and

E~nzyme

activities arise from genetic

fac~

tors that may not be related to the pathogenesis of hypertension.
It had been suggested that these earlier studies, because
of the gross areas investigated, failed to detect changes in
small brain regions and that it is likely that central cardiovascular control is mediated by individual brain areas.
Thus Versteeg and coworkers (1976, 1978) studied smaller
regions and found variations in SHR in regions thought to be
involved in regulation of blood pressure.

Elevated levels of

dopamine (DA) were found in the nucleus interstitialis striae
terminalis and frontal cortex of SHR as compared to WistarKyoto rat.

No differences were found in NE and DA levels in

the hypothalamic nuclei.

Elevated level'S of epinephrine (EPI)

were found in the hypothalamic nuclei investigated.

However,

only the nucleus paraventricularis of SHR showed a significantly higher EPI level.

Many areas of SHR brainstem had

elevated levels of NE, including the A2-region of the nucleus
tractus solitarii.
in this region.

Elevations of DA and EPI were also found

It appears that SHR has elevated catechol-

amine levels in individual brain regions which are supposedly
involved in the central control of arterial blood pressure.
How these changes in brain catecholamine levels are related
to the evolution of hypertension in SHR has yet to be determined.
However, Nakamura and Nakamura (1978) recently reported
observing selective activation of A2-region noradrenergic

9

neurons in young SHR as indicated by an increase in DBH activity.

Elevated activity of this enzyme was also found in" the

locus coeruleus and thoracic intermediolateral cell area of
the spinal cord.

This elevation of DBH activity was not

apparent in adult SHR (Nakamura and Nakamura, 1978).

Young

SHR also had significantly elevated levels of NE and DBH,
confirming earlier studies, which was interpreted as an increase in peripheral sympathetic nerve activity (Roizen et
al., 1975; Nagaoka and Lovenburg, 1976; Nakamura and Nakamura,
1978).

These 'investigators concluded that the selective acti~

vation of.noradrenergic neurons of the A2-regio:h, locus coeruleus, and thoracic intermediolateral cell area, in combination
with the activation of the sympathetic nervous system, initiates hypertension in young SHR (Nakamura and Nakamura, 1978).
Several other studies have indirectly implicated a central involvement in the hypertension of SHR.

L-DOPA

admin-~·

istered to SHR significantly decreased blood pressure.
pling the L-DOPA with a peripheral DOPA decarboxylase
tor potentiated the depressor response.

Cou~

inhibi~

Examination of brain-

stem NE levels showed that a depressor response occurred only
when there was a concomitant rise in brainstem NE levels
(Yamori et al., 1972). ·Judy et al. ( 1978) recently confirmed
these results.

Additionally, they found that SHR were more

sensitive to sympathetic nerve activity inhibition by L-DOPA
combined with a peripheral DOPA decarboxylase inhibitor.
Greater distribution of L-DOPA to tll,e central nervous system
\

of SHR was. eliminate'd as a possible explanation for these
results as the amount of L-DOPA in the cerebral parenchyma

-~
~----~--~-----
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was equivalent in both rat strains (Judy et al., 1978).

It

appears· that there mia.y be a highly significant inverse relationship between bra:lnstem NE levels and blood·pressure
( Yamori et al. , 1972).
Like the brainstem, the hypothalamus has also been implicated in the development of hypertension in SHR.

Yamori and

Okamoto (1969) discovered that when the neural connection between the

posterio~

hypothalamus and mesencephalon was separ-

ated, a significantly greater fall in blood pressure was elicited in SHR as compared to Wistar rat.

Other separations in

the hypothalamus or l)etween the hypothalamus and other brain
structures were ineffective in producing depressor responses.
These results provide evidence of hypothalamic tonic influence
on blood pressure and its participation in pathogenesis of
hypertension in SHR.
Various studies have shown that the posterior hypothalamus mediates pressor responses (Karpus and Kreidl, 1918, 1927)
while the anterior hypothalamus mediates depressor responses
(Folkow et al.,
- 1959, 1964; Phillippu and Schartner, 1976).
EPI and NE may be the neurotransmitters involved in the depressor response (Struyker Boudier and Bekers, 1975; Struyker
Boudier, 1975).

Intrahypothalamic increases in cyclic-AMP

(cAMP) have been shown to result in press.or responses.

Con-

versely, decreases in cAMP result in depressor responses
(Walland, 1975).

Weak electrical stimulations of the poster-

ior hypothalamus, which were ineffective in Wistar rats, were
found to elicit measurable responses in SHR.

Currents above

threshold always elicited greater pressor responses in SHR.

- - - - - - ------------

11
Hypersensitivity of the posterior hypothalamic pressor areas
_of SHR was considerEid as an explanation for these results.
However, possible hypersensitivity of other sites in the
efferent neural pathway could not be excluded (Bunag et al.,

1975).

Hypothalamic concentrations of cAMP has recently been

shown to be lower in SHR than in Wistar-Kyoto rat whereas
cortical levels of c:AMP did not differ.

It was suggested .

that reduced levels of hypothalamic cAMP may be related to
the elevated blood pressure of SHR.

In: any case, these re-

sults indicate a possible alteration of the adenylate cyclasecAMP-phosphodiesterase system in hypothalamic structures of
SHR (Schmid et al., 1978).
Because of the possible variations of catecholamine
levels within certain brain regions of SHR, several behavioral
studies have been performed on this particular rat strain.
Open field tests had indicated that SHR were at a lower emotional state than Wistar rat (Shimamoto and Nagaoka, 1972;
Pappas et al., 1974).

A greater excitement of the cortex of

SHR had been postulated from their apparently greater spontaneous activity (Shimamoto and Nagaoka, 1972; Pappas et al.,

1974; Myers et al., 1977).

Greater cortical excitement may

be related to the finding that SHR were more sensitive to
electroshock seizures.

This increased sensitivity was cor-

related with a slower turnover of NE in the brainstem and
cortex and of DA in the striatum (Goldberg et al., 1975).
Behavioral responses induced by methamphetamine, apomorphine and L-DOPA have been assessed by scoring.

Methamphet-

amine caused greater behavioral excitement in SHR as indicated

12
by a!). increase in

pE~ak

effect and duration of action.

Sub-

cutaneous administration of apomorphine resulted in similar
stereotyped gnawing behavior in both SHR and Wistar rat.
L-DOPA also resulted in similar behavioral responses.

It was

concluded from these drug-induced behavioral changes that SHR
are more susceptible to release of DA from corpus striatum
( Shimamoto and Naga_oka, 1972).
Sidman avoidance response rates showed that the average
avoidance response in SHR increased after the fifth test and
remained significantly higher than that shown by Wistar rat
(Takaori et al., 19'?2).

Rosecrans and Adams (1976) also

observed higher avoidance rates which they interpreted as being in,dicative of a lower emotional· state.

Treatment with

para-chlorophenylalanine (J2.-CPA) resulted in an increase in
avoidance in both strains, but the increase in SHR was not
significant due to the higher initial level.
tryptophan (5-HTP)

n~rkedly

L-5-hydroxy-

lowered the frequency ot avoidance

responses in SHR whereas only a high dose lowered the frequency in Wistar rat.

Treatment with alpha-methyltyrosine

had no effect on the avoidance rates.

L-DOPA produced a

slight increase in avoidance response in Wistar rat, whereas
the same dose_ caused a marked decrease in frequency in SHR.
Since 12.-CPA depleted brain serotonin and 5-HTP increased
brain serotonin, these results indicate that there may be an
abnormality in serotonin metabolism in SHR.

Additionally, the

response to L-DOPA may indicate an alteration in SHR brain
catecholamine metabolism as there were observable increases
in central catecholamine levels (Takaori et al., 1972).

1J
In keeping with the possibility of abnormal serotonin
metabolism in SHR, Ro·secrans and Adams ( 1978) attempted to
correlate changes in serotonin metabolism to changes in behavior.

These investigators found enhanced serotonin turn-

over in cerebral cortex, diencephalon, and brainstem, with
significantly
forebrain.

inc~eased

turnover occurring in the limbic

SHR were found to be less active than the Wistar

rat upon initial testing of spontaneous motor activity, an
observation

incon~istent

with previous studies.

When SHR

were subjected to repeated testing situations they were
found not to habi tuat,e as readily as Wistar rat, as evidenced
by an eventual higher spontaneous activity than Wistar rat.
Similar results were obtained with respect to rearing.

It

was concluded that habituation is an active process which is
retarded in SHR because of hyperfunctional serotonergic
systems· •
. Body temperature studies by Tanaka and others ( 1972)
showed that the body temperature response of SHR to L-DOPA
differed from that displayed by Wistar-Kyoto rat.

These

investigators found that L-DOPA alone was able to cause hypothermia in SHR.

L-DOPA administered alone to Wistar-Kyoto

rat resulted in a hyperthermic response.

Only when L-DOPA

was coupled with a peripheral DOPA decarboxylase inhibitor
pretreatment was a hypothermic response in Wistar-Kyoto rat
observed.

Since L-DOPA-induced hyperthermia is mediated peri-

pherally and hypothermia centrally,, these researchers concluded.that this difference in temperature response was due
to the presence of a more permeable blood-brain-barrier in

--------

~-------~
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SHR.

B.

Apomorphine-Induced Stereotypic Behavior in the Rat
Administration of apomorphine to rats results in its

accumulation within minutes in all brain regions (Butterworth and Barbeau, 1974).

As a consequence of its presence,

a behavioral syndrome is elicited which follows a time course
that parallels this accumulation (Butterworth and Barbeau,

1974).

This behavioral syndrome is known as "stereotyped

behavior", and consists largely of purposeless, repetitive,
compulsive movements.

These movements begin as discontinuous

sniffing which progresses to continuous sniffing concomitant
with repetitive head and forelimb movements.

Increased loco-

motor activity then occurs in the presence of this continuous
sniffing giving the impression of exploratory activity.

This

behavior is eventually replaced by continuous gnawing, biting,
or licking as the rat restricts its motor activity, if any,
to a single area.

The purposeless, repetitive, compulsive

nature of this activity justifies its "stereotyped" label
(DiChiara and Gessa, 1978).
The importance of the corpus striatum in the mediation
of the apomorphine-induced gnawing behavior was demonstrated
very early (Harnack, 1874; Amsler, 192J).

Ernst and Smelik

(1966) narrowed down the location by implanting microquantities of DOPA or apomorphine into various regions of the brain.
The gnaw-syndrome was elicited only when these chemicals were
administered to the dorsal part of the caudate nucleus and
globus pallidum.

No change in behavior was observed when
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either of these drugs was implanted into the ventral caudate
nucleus, nucleus lateralis septi, subthalamic structures, or
the substantia nigra.

It was concluded that the specific area

of the caudate nucleus that is involved in this syndrome is
I

the neostriatum.

It was suggested that accumulation of DA in

this structure, as shown by Bertler and Rosengren (1959), is
responsible for the gnawing behavior and that apomorphine, because of its structural similarity to DA, is able to stimulate
DA receptors thus mimicking the effects of DA (Ernst and Smelik, 1966).

Dose-dependent increases in stereotyped behavior

were observed when apomorphine was injected into the caudate
nucleus while bilateral electrocoagulation of this region inhibited the response to intraperitoneally-administered apomorphine (Nagy and Decsi, 1977).

The course of study on the pu-

tative dopaminergic agonistic activity of apomorphine has taken two routes:
niques, and

~)

1) those which have employed biochemical techthose which have utilized whole animals.

Several studies have determined the amount of DA depletion after inhibition of TH with alpha-methyltyrosine.

These

studies have consistently shown that apomorphine causes a
retardation of DA depletion (Anden et al., 1967; Butcher and
Anden, 1969).

Unilateral transection of the nigrostriatal

pathway interrupts the concentration of DA at striatal receptor sites.

Treatment with the DA receptor blocker, halo-

peridol, after DOPA decarboxylase inhibitor pretreatment, was
found to have no effect on the lesioned side while the intact
side showed an increase in DOPA concentration (Kehr et al.,

1972).

Apomorphine treatment resulted in a bilateral decrease
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in DOPA concentrations which could be antagonized by haloperidol.

Measurement of DA levels indicated that apomorphine

reduced DA to similar levels on the intact side (Kehr et al.;

1972).

Further experiments demonstrated that apomorphine was

able to significantly decrease the extraneuronal metabolite
of DA, homovanillic acid (Roos, 1969).

From these results it

was concluded that apomprphine is able to reduce the activity
of DA neurons via a negative-feedback mechanism due to stimulation of DA receptors (Anden et al., 1967; Butcher and Anden,

1969), and that this feedback mechanism controls the rate of
tyrosine hydroxylation (Kehr et al., .19?2).
Apomorphine was also demonstrated to decrease TH activity
in synaptosomes while haloperidol had little or no effect.
Haloperidol did partially attenuate the inhibitory action of
apomorphine on TH.

It was postulated that haloperidol may be

able to block only one of two actions that apomorphine may
have on TH activity (Christiansen and Squires, 1974).

Besides

apparently reducing TH activity by a receptor-mediated feedback mechanism as a result of direct DA receptor stimulation,
apomorphine may also directly inhibit this enzyme.

Goldstein

and coworkers (1970) found that apomorphine could inhibit TH
as well as inhibit the synthesis of DA from tyrosine in striatal slices.

Haloperidol added to the striatal slices did

not affect the inhibitory action of apomorphine.

Thus it may

be that apomorphine, besides decreasing TH activity indirectly
via a feedback mechanism, may also be able to directly inhibit
TH activity.

This was considered to be in agreement with its

cathechol stucture (Golstein et al., 1970).
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Structural examination of the apomorphine molecule also
sug~ests

vity.

that it is capable of possessing dopaminergic acti-

By studying the. gnaw-syndrome in rats, Ernst ( 1964,

1967) determined a phenylethylamine configuration with a hydroxy-group at the para-position, or at the para- and metapositions of the phenol-ring is necessary for the gnaw-syndrome.

Other studies implicated the requirement of the dihy-

droxytetrahydroaminonaphthalene moiety for the induction of
the gnaw-syndrome (Pinder et al., 1971, 1972), which is supported by molecular orbital calculations using the extended
HUckel theory (Rekker et al., 1972).

These data indicate that

the active structures of dopamine and apomorphine are extremely similar.
The specificity of apomorphine for inducing changes in
DA neuron activity was shown by Anden and others (1967).

Apo-

morphine was found to be ineffective on the flexor reflex in
. spinalized rats in contrast to noradrenergic receptor stimulants.

They also found that apomorphine did not influence

the disappearance of NE from the brain or spinal cord after
TH inhibition with alpha-methyltyrosine.

Furthermore, halo-

peridol, a rather specific DA receptor blocker (Van Rossum,
1966), blocked the effects of apomorphine (Anden et al., 1967).
Demonstration of direct DA receptor stimulation action
by apomorphine has also been shown in animals pretreated with
enzyme inhibitors or catecholamine depletors.

Pretreatment

of rats with alpha-methyltyrosine or alpha-methyldopa did
not block the stereotypic action of apomorphine (Ernst, 1967).
Costall and Naylor (197Ja) found that reserpine, as well as
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alpha-methyltyrosine, enhanced apomorphine-induced stereotyped behavior.

6-0HDA administered intraventricularly to

rats was found to enhance some of the stereotypic effects
(Schoenfeld and Uretsky, 1972) while a separate study showed
potentiation of all stereotypic effects (Price and Fibiger,
1974).

Although finding no significant difference in the log-

dose response curves between rats treated intraventricularly
with 6-0HDA and untreated rats, Jalfre and Haefely (1971) demonstrated that haloperidol completely blocked the gnawing response to apomorphine.

6-0HDA-induced lesions of the caudate

nucleus also resulted in enhanced apomorphine-induced stereotyped behavior (Kelly et al., 1975; Iversen et al., 1975).
An earlier study indicated that bilateral lesions of the substantia nigra with 6-0HDA resulted in furious compulsive gnawing which was far more violent than after the same dose of apomorphine administered to a normal rat (Uhgerstedt, 1971).
These results provide further evidence that apomorphine is
capable of directly stimulating DA receptors.
Besides observing an enhancement of stereotypy in intraventricularly 6-0HDA-treated rats, Schoenfeld and Uretsky
(1972) noted that this treatment abolished gnawing suggesting
that intact dopaminergic neurons are necessary for full
expression of apomorphine-induced stereotypy.

Oxyperitine and

Ro 04-1284 were also found to reduce or abolish the stereotypy (Costall and Naylor, 197Ja).

Electrolytic bilateral

ablation of the substantia nigra or lesions of the ascending
dopaminergic fibers of the nigrostriatal pathway abolish or
reduce apomorphine-induced stereotypy (Costall et al., 1972;
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Costall and Naylor, 197Jb).

From these findings it appears

that the action of apomorphine depends to a great extent on
intact dopaminergic neurons.
Studies which have utilized electrolytic lesions have
been criticized on the basis that this technique not only
disrupts dopaminergic pathways, but also interrupts the function of other pathways.

Unilateral intranigral injection of

kainic acid produces rotation of the treated animal to the
side away from the lesion, or contralateral turning.

Similar-

ly, unilateral electrolytic lesions of the substantia nigra
also result in contralateral turning.

In contrast, uni-

lateral lesion of the nigrostriatal dopaminergic pathway by
intranigral injection of 6-0HDA, which is just as effective
in destroying dopaminergic neurons as electrolytic lesions,
results in turning towards the side of the lesion, or ipsilateral turning.

Since it was shown that kainic acid pro-

duced contralateral turning independently of dopaminergic
nigrostriatal function, it was postulated that non-dopaminergic neurons exist in the substantia nigra which control
turning behavior in a manner opposite to that of the nigrostriatal dopaminergic neurons.

These results were suggested

to provide an explanation for some turning responses obtained
from electrolytic lesions of the substantia nigra or nigrostriatal pathway which are not readily explained by an action
on the nigrostriatal DA system (DiChiara et al., 1977; Olianas
et al., 1978).

Some of these other non-dopaminergic pathways,

which could easily be disrupted by electrolytic lesions, may
be necessary for complete expression of apomorphine-induced
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stereotyped behavior (DiChiara and Gessa, 1978).
In addition to these postulated pathways, other neurotransmitters and brain structures have been implicated in the
mediation of the stereotypic effects of apomorphine.

Thus it

was found that electrocoagulation of the noradrenergicallyinnervated nucleus amygdaloideus lateralis abolished the
gnawing, biting, and licking behavior induced by apomorphine
while intensifying the sniffing behavior and the repetitive
movements.

It was suggested that the nucleus amygdaloideus

lateralis, and therefore noradrenergic neurons, are involved,
either directly or indirectly, in the mediation of the gnawing, biting, and licking components of apomorphine-induced
stereotyped behavior (Costall and Naylor, 1972).

These obser-

vations were similar to those of Schoenfeld and Uretsky (1972).
Intraventricular administration of 6-0HDA may have depleted
the noradrenergic stores of the nucleus amygdaloideus lateralis
thereby abolishing the gnawing, biting, and licking components
of apomorphine-induced stereotypy while allowing the enhancement of the sniffing and repetitive movements.
It is becoming apparent that some of the dopaminergicallyinnervated structures of the mesolimbic forebrain are also
important in the mediation of apomorphine stereotypy.

It was

found that bilateral destruction of the tuberculum olfactorium
markedly reduced apomorphine-induced stereotyped behavior in
the rat (McKenzie, 1972; Costall et al., 1973, 1975).

Destruc-

tion of the nucleus accumbens was less effective than tuberculum olfactorium lesions in reducing the effects of apomorphine while both of these regions were found to be essential
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for the development of sniffing and repetitive head movements
(Costall and Naylor, 1973).

Similarly, lesions of the ascend-

ing dopaminergic fibers to the mesolimbic forebrain reduced
apomorphine-induced stereotyped behavior.

In contrast to

reductions, Kelly and coworkers (1975) found that 6-0HDA
lesions of the nucleus accumbens enhanced the sniffing behavior upon subsequent treatment with apomorphine.

These

results indicate that the mesolimbic forebrain is important
in mediating the sniffing and repetitive movements induced
by apomorphine.

A detailed examination (Costall et al., 1975) of the
stereotypic effects induced by apomorphine revealed that these
effects can be differentiated into two dose-dependent components.
Low doses of apomorphine result in the appearance of the lowintensity component which consists of sniffing, and repetitive
head and limb movements.

Higher doses of apomorphine result in

the high-intensity component consisting of gnawing, biting, or
licking.

By various central lesions and subsequent administra-

tion of apomorphine, these two components were found to be
mediated by different brain regions.

Bilateral lesions of

the caudate putamen (neostriatum) failed to have any effect
on apomorphine-induced stereotypy (Divac, 1972; McKenzie,

1972; Costall et al., 1973, 1975).

Intracaudate administra-

tion of apomorphine resulted in the development of periodic
biting without sniffing and repetitive head and limb movements.

Lesions of the substantia nigra abolished the biting

response without affecting the low-intensity component.
Lesions of the nucleus accumbens abolished the sniffing
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response to apomorphine while enhancing the intensity of the
biting component.

Injection of apomorphine into this nucleus

resulted in sniffing behavior that was dose-dependent.

Bit-

ing was also observed but did not appear to be dose-dependent.
Lesions of the tuberculum olfactorium also abolished the lowintensity component.
reduced.

However, the biting component was also

Administration of apomorphine into the tuberculum

olfactorium resulted in the development of both high- and
low-intensity components of stereotypy.

As with the nucleus

accumbens, the intensity of sniffing appeared to be dosedependent whereas the biting response remained periodic at
all doses.

It appears that the high-intensity component of

apomorphine-induced stereotyped behavior is mediated largely
by the extrapyramidal systems, while the low-intensity component is mediated by the mesolimbic system (Costall et al.,
1975).
Recently, Ljungberg and Ungerstedt (1977a) reported
observing two independent behavioral patterns elicited by
subcutaneous (s.c.) injections of apomorphine.

These two

behavioral patterns seem to follow the loW- and high-intensity
components described by Costall et al. (1975).

Low-intensity

behavior was observed when apomorphine (as the base) was
dissolved by heating and injected s.c. into the neck, or
when it was dissolved by heating together with a high concentration of ascorbic acid and injected s.c. into the flank or
neck.

High-intensity behavior resulted when apomorphine,

dissolved by heating, was injected s.c. into the flank.

Addi-

tionally, it was found that these results were not merely due

--~---········----·---
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to differences in dose as the low-intensity responses could
not be obtained by lowering the dose of the high-intensity
treatment, and the high-intensity responses could not be obtained by increasing the dose of the low-intensity treatment.
Failure of being able to change the intensity of the response
by changing the dose of apomorphine suggests that the sniffing and repetitive head and limb movements are not of a lower
intensity than compulsive gnawing as previously suggested.
Additional studies showed that apomorphine-induced gnawing is greatly affected by such factors as test environment
and experimental design.

Locomotion, which usually occurs

simultaneously with the apomorphine-induced sniffing behavior,
was shown to be essentially independent of these factors.

It

was found that restricting an animaL'.s ability to locomote by
restricting its area in which to move did not increase its
gnawing behavior.

However, it was shown that pretreatment of

these rats with a dose of clozapine that is able to antagonize apomorphine-induced locomotion without affecting gnawing behavior could change the locomotor behavior to gnawing
behavior.

It was suggested that these results indicate that

apomorphine-induced locomotion is more compulsive than the
so-called "compulsive gnawing" (Ljungberg and Ungerstedt,

1978).

c.

Dopaminergic Involvement in Control of Locomotor Activity
in Rat
A role for DA has been suggested in the control of

motor activity in the rat.

loco~

Marked increases in both locomotor
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activity and brain levels occurred when rats were peripherally
administered L-DOPA coupled with a DOPA decarboxylase inhibitor
pretreatment.

Although NE levels remained unchanged, increases

in motility only occurred in the presence of sufficient NE
(Ahlenius and Engel, 1971; Maj et al., 1971; Friedman and Gershon, 1972).

These results agreed with an earlier study (Ever-

ett and Weigand, 1962) which indicated that both DA and NE were
important in L-DOPA-induced locomotor activity.

L-DOPA coupled

with a monoamine oxidase inhibitor (MAO-I) pretreatment resulted in an increase in brain levels of both DA and NE, as
well as stimulating locomotor activity (Green and Kelly, 1976;
Heal et al., 1976).

Rats pretreated with a DBH inhibitor

known to reduce brain NE concentration had no effect on the
N~O-I/L-DOPA-induced

locomotor activity (Green and Kelly, 1976).

Dopaminergic receptor blockers were found to antagonize the
increase in activity (Heal et al., 1976).

Thus it appears

that DA receptor stimulation is necessary for locomotion
while the role of NE remains equivocal.
Intraventricular injection of DA was found to result in
an increase in locomotor activity that was dose-dependent.
Examination of brain levels of DA and NE indicated that a low
dose of DA did not result in significant changes whereas a
high dose resulted in significantly higher levels of DA which
gradually decreased as NE levels increased (Malec and Kleinrok, 1972).

Costal~

and coworkers (1975, 1976a) observed

dose-dependent hyperactivity after bilateral injection of DA
into the nucleus accumbens.

Nialamide (Pijnenburg and Van

Rossum, 1973; Costall and Naylor, 1975; Costall et al., 1976a)
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or reserpine/nialamide pretreatments (Anden and Jackson,
1975) were

~ound

to strongly enhance locomotor activity.

Bilateral administration of NE to this nucleus after nialamide pretreatment only slightly enhanced locomotor activity
(Pijnenburg and VanRossum, 197.3).

Bilateral injection of

DA,into the tuberculum olfactorium resulted in periodic increases in locomotor activity (Costall and Naylor, 1975)
whereas only a slight to moderate increase occurred after
administration to the caudate nucleus (Pijnenburg and Van
Rossum, 197.3).

Although it appears that dopaminergic recep-

tors of the nucleus accumbens are involved in the control of
locomotor activity, the possible involvement of NE could not
be conclusively excluded by these studies.
Later studies performed by Costall and Naylor (1976a)
showed that the dose-dependent increases in locomotor activity produced by bilaterally-applied DA to the nucleus accumbens of nialamide pretreated rats could be antagonized by
intraperitoneal administration of the so-called typical DA
receptor blockers (haloperidol, fluphenazine, pimozide, clothiapine) and atypical DA receptor blockers (clozapine, sulpiride, thioridazine).

Systemic administration of pimozide to

reserpine/nialamide pretreated animals effectively antagonized
the locomotor activity produced by DA injected bilaterally
into the nucleus accumbens (Jackson et al., 1975).

The alpha-

adrenergic antagonist, phenoxybenzamine, and the beta-adrenergic antagonist, propranolol, were both ineffective in blocking the hyperactivity (Jackson et al., 1975).

These studies

provide further evidence that dopaminergic receptor mechanisms,
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while not necessarily noradrenergic receptor mechanisms, are
involved in the control of locomotor activity.
Several other studies have attempted to determine the
importance of DA and NE in the control of locomotor activity.
Pijnenburg and coworkers (1975a) used amphetamine to differentiate the contribution of these two amines to the control of
locomotor activity.

Haloperidol administered bilaterally

into the nucleus accumbens blocked amphetamine-induced hyperactivity while administration of the alpha-adrenergic antagonist, phentolamine, or propranolol, did not significantly
inhibit locomotor stimulation.

Bilateral administration of

haloperidol into the caudate nucleus did not inhibit amphetamine-induced locomotor activity.

Haloperidol antagonized

the locomotor stimulation by both DA and NE injected into
the nucleus accumbens of nialamide pretreated rats (Pijnenburg et al., 1975b).

Phentolamine, on the other hand, poten-

tiated the hyperactivity produced by both of these amines,
suggesting that the stimulation of locomotor activity induced
by NE is the indirect result of dopaminergic mechanisms
(Pijnenburg et al., 1975b).

NE and the alpha-adrenergic ago-

nists, clonidine and phenylephrine, injected into the nucleus
accumbens of non-pretreated animals produced depression
rather than stimulation while DA resulted in a significant
increase in locomotor activity which could be antagonized by
haloperidol (Pijnenburg et al., 1976).

These results agree

with the earlier studies which implicate dopaminergic receptors of the nucleus accumbens in the control of locomotor
activity.

Although the results on NE inv6lvement remain
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equivocal, this neurotransmitter may be indirectly involved
via dopaminergic systems in the control .of locomotor activity.
Apomorphine unexpectedly produced both stimulant and
depressant effects when applied bilaterally into the nucleus
accumbens, but produced locomotor stimulation when applied
bilaterally into the tuberculum olfactorium (Pijnenburg et
al., 1976).

In contrast, Jackson and coworkers ( 1975J found

apomorphine induced locomotor activity similar to that produced by DA applied bilaterally into the nucleus accumbens.
Systemic administration of apomorphine was shown by Maj
et al. (1972) to stimulate an increase in locomotor activity.
Haloperidol and spiroperidol blocked the increase induced by
lower doses of apomorphine while higher doses were able to
overcome the blockade.

Phenoxybenzamine antagonized the

higher doses suggesting the involvement of NE in apomorphineinduced hyperactivity.

Furthermore, alpha-methyltyrosine,

dimethyldithiocarbamate, and disulfiram partly inhibited the
locomotor effect of apomorphine.

It was concluded that both

DA and NE are involved in the control of motility in rats,
and that apomorphine induces hyperactivity in rats by direct
stimulation of DA receptors (Maj et al., 1972).

In a follow-

ing report, Maj and coworkers (197J) found that alpha-methyltyrosine did not significantly affect the locomotor response,
although the motility induced by apomorphine was reduced by
this treatment.
Systemic administration of apomorphine to rats with
bilateral 6-0HDA lesions of the nucleus accumbens resulted in
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an enhanced locomotor response which could be blocked by pimozide (Iversen et al., 1975).
In contradiction to their results obtained with DA,
Costall and coworkers (1975) found that bilateral injections
of apomorphine directly into the nucleus accumbens resulted
in activity that was indistinguishable from that exhibited
by animals receiving solvent injections.

In later studies,

Costall and Naylor (1976b) discovered that systemically-administered apomorphine in substereotypic doses was able to
antagonize, in a dose-dependent manner, the hyperactivity
induced by DA administered directly into the nucleus accumbens.

Furthermore, apomorphine administered directly into

the nucleus accumbens was able to antagonize the locomotor
stimulant effect of directly applied DA.

It was suggested

that these results may indicate that while apomorphine has
affinity for the DA receptors in the nucleus accumbens, it
may lack intrinsic activity.

These authors also speculated

on the possible activity that apomorphine may have on serotonin mechanisms in the nucleus accumbens (Costall and Naylor,
1976b)~

Earlier studies had shown that lesions of the midbrain
raphe nucleus resulted in marked decreases in the levels of
serotonin and its metabolite, 5-hydroxyindoleacetic acid
(5-HIAA), in the forebrain.

A concomitant increase in loco-

motor activity was observed suggesting that serotonin may play
an inhibitory role in the control of locomotor activity (Kostowski et al., 1968).

Electrolytic lesions of the medial ra-

phe nucleus resulted in an enhanced locomotor response to apo-

-----------
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morphine (Grabowska, 1974) while pretreatment of animals
with the serotoninolytics, methysergide and brom-lysergic
acid diethylamide, also enhanced apomorphine-induced hyperactivity (Grabowska and Michaluk, 1974).

It was hypothesized

that serotonin plays an inhibitory role in apomorphineinduced locomotor stimulation in rats.

Since it had also

been observed that the decline of apomorphine-induced hyperactivity was inversely related to the elevation of 5-HIAA concentration, it was suggested that apomorphine activates central serotonin neurons and thereby attenuates its own stimulatory effect on locomotor activity (Grabowska et al., 197.3a).
Indirect support for this hypothesis was provided by Costall
et al. (1976b) when they showed that serotonin injected into
the nucleus accumbens resulted in dose-dependent reductions
in the hyperactivity induced by prior injections of DA.
ger doses completely abolished the DA effect.

Lar-

When forebrain

concentrations of serotonin were reduced by lesions of the
medial raphe nucleus, it was found that the hyperactivity
response to DA was markedly enhanced.

These results were

suggested to indicate that the facilitatory effect of DA on
locomotion may be modulated by an inhibitory influence from
serotonergic mechanisms (Costall et al., 1976b).

It was also

noted that the antagonism of the DA-induced locomotor activity
by serotonin after injections of these putative neurotransmitters into the nucleus accumbens was similar to that produced by apomorphine administered in the same manner (Costall
and Naylor, 1976b).

)0

D.·· Apomorphine- And L-DOPA-Induced Hypothermia in Rat
Apomorphine has been consistently reported to cause a
decrease in the core body temperature of the rat (Kruk and
Brittain, 1972; Kruk, 1972; Yehuda and Wurtman, 1972; Hansen and Whisaw, 1973; Grabowska et al., 1973b; Grabowska,
1974; Scheel-Kruger and Hasselager, 1974; Chiel et al.,
1974; Przewlocki, 1976, 1977; Ary et al., 1977; Cox and Lee,
1977a, 1977b).

Various injection methods have been used in

these numerous studies.

Kruk and Brittain (1972) found that

intraventricular injection of apomorphine resulted in a fall
in core temperature along with a rise in skin temperature.
Kruk (1972) reported a dose-dependent decrease in core body
temperature and an increase in skin temperature after intraventricular administration of apomorphine.

Pretreatment

with pimozide antagonized the activity of apomorphine.
Similarly, several other studies have shown that pimozide
and spiroperidol can block the hypothermic action of systemically-administered apomorphine (Yehuda and Wurtman, 1972;
Grabowska et al., 1973b).

It appears that apomorphine

mediates hypothermic responses through activation of DA receptors.
Development of tolerance to the hypothermic effects .of
apomorphine has been shown to occur with repeated administration.

Chiel and coworkers (1974) showed that weekly injec-

tions of apomorphine resulted in a gradual decline in the
hypothermic response.

It was suggested that the development

of tolerance was due at least in part to alterations in the
sensitivity of DA receptors.
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The site of action of apomorphine has been demonstrated
by Cox and Lee (1977a, 1977b) to reside within the preopticanterior hypothalamus.

Administration of apomorphine into

the preoptic-anterior hypothalamus and the lateral ventricle
resulted in hypothermic responses.

The response elicited from

intrahypothalamic administration was of greater magnitude and
took significantly less time to develop.

A separate study

(Ary et al., 1977) reported similar results.

In addition it

was found that hypothermia induced by systemic injections of
apomorphine could be antagonized by pretreatment with pimozide
injected into the rostral hypothalamus.

Intraventricular

administration of pimozide did not block the hypothermic response to systemically-administered apomorphine.

Tolerance

was discovered to·occur to repeated injections of apomorphine
given both systemically and intrahypothalamically.

Repeated

injections of apomorphine into the lateral ventricle did not
result in the development of tolerance.

It was suggested

that apomorphine can induce hypothermia via two different
types of DA receptors at two different sites:

1) in the ros-

tral hypothalamus where the receptors develop tolerance and
where the temperature is due to a downward shift in the set
point as determined by behavioral thermoregulation studies;
and g) in areas surrounding the lateral ventricle where receptors do not develop tolerance (Ary et al., 1977).

The possi-

bility of a relay from the lateral ventricular sites to the
hypothalamus was also suggested.
Since serotonin has been shown to be involved in the
control of locomotor activity, the possible involvement of
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this putative neurotransmitter in apomorphine-induced hypothermia has also been investigated.

Grabowska (1974) found

that lesions of the medial raphe nucleus attenuated the hypothermia caused by apomorphine.

Contradictory results were

reported by Przewlocki (1977) who found that electrolytical
and chemical lesions of both the dorsal and medial raphe
nuclei prevented apomorphine-induced hypothermia.

Lesions

of the medial raphe nucleus by both methods did not affect
the fall in body temperature whereas lesions of the dorsal
raphe nucleus attenuated the hypothermia.

Additionally,

bilateral electrolytic lesions of the caudate nucleus, substantia nigra, or nucleus accumbens did not affect or potentiated the hypothermic response.

It was concluded that meso-

limbic dopaminergic neurons were not involved in the hypothermia elicited by apomorphine, whereas the neurons of the
dorsal raphe nucleus may be involved in this action of apomorphine (Przewlocki, 1977).

On the basis of these results,

it has been suggested that part of the hypothermic action of
apomorphine may possibly be the result of indirect activation
of serotonergic neurons which originate in the midbrain (Grabowska, 1974; Przewlocki, 1976).
The results of locomotor activity studies have suggested
that L-DOPA-induced increases in locomotion in the rat are
related to the conversion of L-DOPA to DA with subsequent
activation of DA receptors.

L-DOPA has also been shown to

decrease body temperature which could be assumed to also be
due to the formation of DA and stimulation of DA receptors in
the preoptic-anterior hypothalamus.

However, Reichenburg and

--------
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Vetulani (1973) reported that hypothermia induced by intraventricular injection of L-DOPA was unaffected by spiroperidol.

Maj and Pawlowski (1973) confirmed these results by

showing that L-DOPA administered with a peripheral DOPA decarboxylase inhibitor also elicited a hypothermic response
which was unaffected by spiroperidol or pimozide.

Additionally,

the L-DOPA treatment caused a decrease in brain serotonin
levels while increasing .5-HIAA levels.

Since the serotonin

depletor £-CPA attenuated both the fall in body temperature
and the changes in brain serotonin and .5-HIAA levels, it
was suggested that the release of serotonin may be responsible
for L-DOPA-induced hypothermia.

E.

Statement of the Problem
Several studies have indicated possible alterations in

the levels and metabolism of brain monoamines in SHR (Yamori
et al., 1970; Nakamura et al., 1971; Shimamoto and Nagaoka,
1972; Sjoerdsma, 1972; Goldberg et al., 197.5; Rosecrans and
Adams, 1976; Versteeg et al., 1976, 1978).

Several of these

have been neuropharmacological in nature (Shimamoto and
Nagaoka, 1972; Rosecrans and Adams, 1976) and only one has
attempted to examine a central neurotransmitter system in any
detail.

This study (Rosecrans and Adams, 1976) attempted to

correlate alterations in behavior of SHR to alterations in
serotonergic mechanisms.

This study found an increased turn-

over of serotonin and a decreased ability to habituate to
stimuli which was suggested to represent a hyperfunctional
serotonergic system in SHR.

Neither of the catecholaminergic
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systems have been studied in any detail.

However, several

studies utilizing L-DOPA have indicated changes in catecholamine metabolism in SHR (Shimamoto and Nagaoka, 1972; Tanaka
et al., 1972).

These L-DOPA-induced changes rely largely on

presynaptic events as tpe L-DOPA must be converted to DA
and/or NE, or release of serotonin before it can exert its
effect.

Changes in presynaptic levels and metabolism of the

catecholamines could lead to alterations in postsynaptic
events such as changes in sensitivity of postsynaptic receptors.
There are extremely few studies which have examined postsynaptic receptors in SHR by using direct acting catecholamine receptor agonists.

One study used the direct acting

DA agonist, apomorphine, to compare drug-induced behavior
between SHR and Wistar rat (Shimamoto and Nagaoka, 1972).
This study found no difference in response between the two
rat strains indicating no change in receptor sensitivity of
striatal DA receptors.

However, receptor sensitivity of two

other central dopaminergic systems remain unstudied.

There-

fore there seems to be little information on DA receptor
sensitivity in SHR.
Since body temperature and Sidman avoidance responses
to L-DOPA were reported to differ significantly from normotensive controls (Shimamoto and Nagaoka, 1972; Tanaka et al.,
1972), suggesting possible alterations in dopaminergic
metabolism and/or DA receptor sensitivity, the present study
was undertaken to examine central DA receptor sensitivity of
SHR.

Apomorphine was selected as the dopaminergic agonist as

it is postulated to be a direct acting agonist, and it is

. f

t

~
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capable of inducing three responses: 1) stereotyped behavior;
.f.) locomotor activity; and

J.) hypothermia.

As stereotyped

behavior is mediated via the neostriatum and mesolimbic
forebrain, locomotion via the mesolimbic forebrain, and
hypothermia via the hypothalamus, determination of possible
alterations in central DA receptor sensitivity in SHR will be
attempted by comparing the three apomorphine-induced responses
obtained from SHR to those obtained from normotensive rats.

MATERIALS AND METHODS
A.

Animals and Blood Pressure Measurement
Three rat strains were utilized in this study:

spontaneously hypertensive rat (SHR); Z) the
rat (WKY); and

1)

the

Wistar~Kyoto

l) the Wistar rat (NWR). The SHR and WKY

were obtained from the breeding colony at the University of
the Pacific School of Pharmacy.

Both the SHR and WKY colonies

were descendants of the original colonies in Japan.

The

breeding stock was obtained from Dr. J.V. Levy of the Pacific
Medical Center, San Francisco, Calif.

SHR has been maintained

by brother-sister matings of animals selected for their high
systolic blood pressure (greater than 180 mmHg).

WKY has been

maintained by randomized matings of animals selected for their
normal blood pressure (a systolic blood pressure no higher
than 145 mmHg).
Gilroy, Calif.

NWR were obtained from Simonsen Laboratories,
Upon arrival, these rats were housed in

groups of not more than 20 per cage in an animal room which
was not under a 12 hour light-dark cycle but which was maintained at 22 26 °C until they reached proper age and weight
(longer than one week).
were measured.

At this time their blood pressures

SHR and WKY were housed in the same animal

room which was maintained at 22-26 °C under a 12 hour light-
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dark cycle until their blood pressures were measured.

Each

strain was given food (Simonsen Laboratories Custom Lab
Diet) and water ad libitum up until the time of the experiments.

All animals used were drug-naive males ranging from

12 to 15 weeks of age. ·At this age the weights of the animals
ranged from 250 to J50 grams.

Animals were selected before

the experiments were performed on the basis of their systolic
blood pressures.
Systolic blood pressures were determined in unanesthetized rats by the previously described plethysmographic tailcuff method (Williams et al., 1939; Del Greco et al., 1953;
Bunag, 1973).

Before measuring, the rats were pre-warmed in

a metal cage floated in a hot water bath (Precision Scientific, Company) for 10 min at 37 °C for the purpose of increasing blood flow in the tail (Rand et al. , 196 5) • After
warming, the animals were placed in a rat holder connected
to a temperature control unit (Narco Biosystems) which was
set at "8".

A pressure cuff (E & lVI Instrument Company) was

placed on the base of the tail behind which a bulb for the
pneumatic pulse transducer (E & lVI Instrument Company) was
placed.

The bulb was held in place by the barrel of a 5 cc

syringe which had been cut down to the same length as the
bulb.

The pneumatic pulse transducer was connected to an

electrosphygmograph (E & lVI Instrument Company) which was in
turn connected to the pressure cuff and a desk model physicgraph (E & lVI Instrument Company; type DlVIP-4A).

The cuff was

inflated by a blood pressure cuff pump (E & lVI Instrument
Company) which also automatically deflated the cuff.

Upon
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release of the pressure, blood flowed back into the tail.
This blood flow set up pulsations which could be picked up
by the pneumatic bulb which transmitted it to,the pneumatic
pulse transducer.

The signals from the pneumatic pulse trans-

-

ducer were amplified by an amplification unit (Narco Biosystems) in the physiograph.

The unit was calibrated before

each session of blood pressure recordings by setting the
deflection of the tracing stylus to 2.5 em on the graph paper
(Narco Biosystems) for every 100 mmHg pressure.

The 100 mmHg

pressure was provided by pressing the "Calibrate" button on
the electrosphygmograph.

A minimum of three pressure mea-

surements were taken on each rat.

After their blood pres-

sures were measured, the animals were divided into groups of
three and maintained on a light-dark cycle of 800 to 2000 hr
light for approximately one week before being used for an
experiment.

B.

Stereotyped Behavior
Animals were placed individually into clear plastic

cages (Maryland Plastics; 44 em x 23 em x 20 em) and allowed
to acclimate one hour before injection.

The bottoms of the

cages were filled approximately 1-1/2 em deep with bedding
material (KC Pharmacal) upon which the animals could gnaw or
bite.

Screens constructed of cardboard were placed between

each of the cages to avoid the possibility of the animals
influencing each others behavior.
Animals were injected with apomorphine at 5 min intervals
with the first injection being made at 1300 hr.

The apomor-
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phine-induced stereotyped behavior was then assessed by scoring every 5 min according to the rating scale shown in Table
I.

Scores were then cumulated into 15 min-intervals for each

rat for statistical analysis.

All observations and scoring

were made by several experienced observers who were not blind
to the treatment.

They assessed stereotyped behavior at two

doses of apomorphine.

The susceptibility of the rat strains

to antagonism of apomorphine-induced stereotyped behavior was
also assessed after pretreatment with haloperidol.

E.

Locomotor Activity
After the animals had been on the light-dark cycle of

800 to 2000 hr for one week, they were weighed in the morning and placed in a clear plastic cage of the same make as
those used for the stereotyped behavior experiments.

Unlike

the stereotyped behavior experiments, these experiments were
run with three animals per group in order to allow for normal
social interactions.

During these experiments the animals

were allowed access to food (which was placed within the cage),
but were not allowed water as drinking interfered with the
activity counts recorded by the activity meter.

At 1600 hr

of the first day each of the animals was injected with
1 ml/kg of vehicle.

At this time, the water bottle was re-

moved from the cage.

The spontaneous activity of the animals

was measured overnight with the lights going off at 2000 hr
and on at 800 hr.

Each animal was again weighed on the

morning of the second day.
ad libitum at

thi~

time.

Water was given to the animals
At 1600 hr of the second day the
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TABLE I

Stereotyped Behavior Rating Scale
Assigned Scorea

Behavior Displayed:

0

Behavior indistinguishable from
that displayed by untreated animals.

1

Periodic sniffing, and/or repetitive head and limb movements.

2

Continuous sniffing with exploratory activity; and repetitive
head and limb movements.

J

Occasional or periodic gnawing,
biting, or licking, and exploratory activity with continuous
sniffing.

-

"

H

4

Persistent and intense gnawing,
biting, or licking with locomotion restricted to a small area.

5

Compulsive gnawing, biting, or
licking at one location.

(This rating scale was modified from those of Ernst (1965,

1967), and Costall and Naylor (1973)).
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animals were injected with a 2.0 mg/kg dose of apomorphine,
the water was removed, and the activity recorded for 2:
hr.

Recordings were begun each day immediately after the

third rat had been injected.
Activity was measured by a Model "S" Selective Activity
Meter (Columbus Instruments Company) with its sensitivity
set at "5.0".

The meter was always within a quiet room, and

was allowed a warm-up period of at least 1/2 hr before the
beginning of an experiment.

Cumulative activity counts were

recorded automatically every six min by a PC-1 printing
counter (Columbus Instruments Company).
The activity counts from the first day (overnight locomotor activity) were divided into 2 hr-intervals for each
group of three rats for the purpose of determining whether
spontaneous locomotor activity differs between the three rat
strains.

To determine the effect that apomorphine had on

locomotor activity, the activity counts'obtained for the
first 1-1/2 hr from each group of three rats for each day
were divided into 18 min-intervals.

The activity counts

obtained during each 18 min-interval of the first day (vehicleinjected) were then subtracted from the activity counts

ob...,~

tained from the corresponding 18 min-interval of the second
day (apomorphine-injected).

This difference was considered

to be the locomotor activity induced by apomorphine.

D.

Body Temperature
Animals were placed individually into metal cages

()0.0 em x 2).5 em x 15.0 em) covered on the bottom with

_

- - -

-----------------------------~~---------

------
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bedding material.

The animals were allowed to acclimate to

the cages for 1 hr before beginning the experiment.

Body

,,,.,

temperature was determined rectally by use of a Model 43 TA
telethermometer (Yellow Springs Instruments Company) with flexible thermistor probe (number 402).

The probe was inserted

4 em into the rectum and the temperature was allowed to stabilize before being recorded (at least 30 sec).

Experiments

were started at 1100 hr when body temperature was first measured and recorded for each rat.

Temperatures were then taken

every 15 min for the entire duration of the experiment.

The

rats remained untreated for the first 2 hr of the experiment
thereby allowing their body temperatures to equilibrate.

Apo-

morphine or L-DOPA was injected immediately after the 1300 hr
body temperature measurement.
the baseline temperature.

This temperature was used as

Carbidopa was administered as a

pretreatment 1 hr prior to the injection of L-DOPA and was
injected immediately after the 1200 hr temperature reading.
Haloperidol, in the experiments in which blockade of apomorphine-induced hypothermia was attempted, was administered
immediately after the 1230 hr temperature recording.

Tempera-

tures were taken for another 2-1/2 hr after the injection of
apomorphine or L-DOPA.

Changes in body temperature were deter-

mined for each rat by subtracting the baseline temperature
from the temperature obtained every 15 min after the administration of apomorphine or L-DOPA.

E.

Drugs
Apomorphine (APO) (Merck, Sharp, and Dohme Research
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Laboratories) was used and weighed out as the hydrochloride
salt.

This drug was dissolved in

immediately prior to injection.

double~distilled

water

Concentrations of 0.25 and

0.35 mg/ml of APO were prepared by diluting a volume of 0.5
m~ml

concentration of APO with an equal volume of double~

distilled water, and by diluting 7.0 ml of the 0.5 mg/ml
concentration with J.O ml of d9uble-distilled water, respectively.

APO was administered in a volume of 1 ml/kg.

L-DOPA (ICN Pharmaceuticals; and Sigma Chemical Company)
and carbidopa (Merck, Sharp, and Dohme Research Laboratories)
were used in their base form, and were prepared by a modification of a previously described method (Ahlenius and Engels,
1971).

The 50 mg/kg and 100 mg/kg doses of L-DOPA, and carbi-

dopa (50 mg/kg dose was used in all experiments) were prepared
in the following manner&

1)

75 mg or 150 mg of L-DOPA, or

75 mg of carbidopa was dissolved in 0.4 ml of approximately
2N HCl; 2) 2.2 ml of a propylene glycol solution was added to
this acidic solution; J) this solution was in turn neutralized
by 0.4 ml of approximately 2N NaOH.
was prepared by:

1)

A 25 mg/kg dose of L-DOPA

dissolving 37.5 mg of L-DOPA in 0.2 ml

of approximately 2N HCl; £) to which was added 2.6 ml of the
propylene glycol solution; and

1) this solution was in turn

neutralized with 0.2 ml of approximately 2N NaOH.

These drug

preparations totaled J.O ml and were injected immediately
after their preparation as the L-DOPA or carbidopa would begin
to precipitate.

The particles that did precipitate out were

held in suspension by the propylene glycol.

Both the L-DOPA

and carbidopa were injected in a volume of 2 ml/kg.

44
The propylene glycol solution was prepared by diluting

J.O ml of propylene glycol (U.S.P., Fisher Scientific Company) with 7.0 ml of double-distilled water.

2N HCl was

prepared by diluting concentrated hydrochloric acid (Mallinckrodt) while the 2N NaOH was prepared by dissolving the proper amount of sodium hydroxide pellets (J.T. Baker Chemical
Company) in double-distilled water.
Haloperidol (HAL) was obtained in pre-prepared ampuls
of 5 mg/ml in a volume of 1 ml-CHardol_R_o-y-rv1cN1ri_l_)-.-N-i;"n"'e.-:--~--tenths ml of the pre-prepared haloperidol solution was diluted with double-distilled water to a total of 15 ml to obtain a concentration of

O.J mg/ml haloperidol. A concentra-

tion of 0.5 mg/ml haloperidol was prepared by diluting 0.9 ml
of the pre-prepared haloperidol solution with double-distilled
water to a total of 9.0 ml.

These solutions were kept refrig-

erated after being placed in vials wrapped with aluminum
foil.

HAL was administered in a volume of 1 ml/kg.
A lithium chloride solution was prepared from lithium

carbonate (J.T. Baker Chemical Company, Reagent Grade) by
dissolving 7.389
chloric acid.

gm

This solution was brought to 100 ml with double-

distilled water.
2 mEq/ml.

to neutrality with concentrated hydro-

The resulting concentration of lithium was

A sodium chloride solution was prepared by dis-

solving 11.700

gm

of sodium chloride (J.T. Baker Chemical Com-

pany, Reagent Grade) in 100 ml of double-distilled water.
resulting concentration of sodium was 2 mEq/ml.

The

These solu-

tions were used for chronic treatment of the three rat strains.
The treatment schedule consisted of daily administration of
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2 mEq/kg lithium or sodium at 1000 hr for 14 consecutive days
(modified from Friedman and Gershon (197J)).

On the 14th

day a body temperature experiment using a 0.5 mg/kg dose of
APO was performed on these chronically treated animals.
A hydralazine HCl solution was prepared by diluting 5
ampuls of 1 ml ampuls containing 20 mg hydralazine HCl (CIBA)
to 1000 ml so that the resulting concentration of hydralazine
HCl was 100 mg/1000 ml.

This solution was given to a group

o1· slili ad-r1oi-tl.II'!f1n place of-their drinKing water for 4 weeks.
At the end of the 4 week period, a body temperature experiment was performed on these SHR.

The average volume of solu-

tion consumed by each rat during the course of the antihypertensive therapy was determined to be 25 ml/24 hr.

From this

information it was calculated that each rat received approximately 2.5 mg hydralazine HCl for each 24 hr.
All drugs were administered intraperitoneally (except for
the hydralazine HCl) slightly to the right of the abdominal
midline approximately half-way between the sheath and the
sternum.

One-milliliter tuberculin syringes equipped with

25 G, 5/8-inch long needles (Becton-Dickinson) were used for
all injections.

F.

Determination of Serum Lithium Levels
A group of animals was selected for the purpose of deter-

mining serum lithium levels.

These animals were chronically

treated with lithium or sodium in the same manner as those
animals used for the temperature experiments.

At 1JOO hr of

the 14th day these animals were decapitated and bled into open-

-~~----~--~---~--
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ed vacutainer tubes.
settle out.

The cells were allowed to coagulate and

The sample was then centrifuged to obtain the

serum to be analyzed for lithium.

This analysis was performed

by medical technologists at the Stockton Medical Pathology
Group.

As a result of sending the samples out, the analysis

was performed by three different individuals on three separate
occasions.

These individuals were blind to the treatment

schedule and therefore to whether the samples contained lithium
or sodium.

They analyzed the samples according to the follow-

ing procedure:
A Varian Model 1000 atomic absorption spectrophotometer
was used to analyze the serum for lithium.

A light source of

671 millimicrons was supplied by a Varian lithium hollow cathode lamp with an operating current of 0.5 milliamps.
slit width was set at 0.5 nanometers.

The

The burner was supplied

with acetylene at 12 pounds per square inch with a flow of 3
units on the instrument meter and air at 43 pounds per square
inch with a flow of 5 units on the meter.

The lithium stan-

dard (Instrumentation Laboratories) contained 1.0 mEq/1
1.5

%.

~

A stock solution of this standard was prepared by di-

luting 1:10 with a diluent containing 14.0 mEq/1 sodium and
0.5 mEq/1 potassium.

Two levels of control serum (by Hyland

division of Travenol Laboratories) were reconstructed according to the manufacturer's instructions and assayed with each
group of unknown serum.

Lithium control values were 0.5

0.1 mEq/1 for level I and 1.5

~

0.1 mEq/1 for level II.

+

The

unknown and control sera were diluted volumetrically with distilled water.

Serum lithium concentration was determined by

--------"7~-~~--=-~-~-~---~
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the following procedure: 1) distilled water was aspirated
first at a rate of approximately

4.5 ml/min and the percentage

absorbance adjusted to 0.00 on the visual scale and 000 on
the digital indicator; 2) the diluted standard was aspirated
and the digital indicator set to 010 by the concentration , ....
mode; .1) diluted controls and unknowns were then assayed and
the initial concentrations of the unknowns were calculated by
multiplying the number of units on the digital indicator by
u--;-1-mEq/unrt-tHansen,

G.

i-9&5-)~.----------------------

Ambient Temperature
All experiments were carried out at an ambient tempera-

ture of 23 + 1 °C.

H.

Statistics
The data obtained for the following:

1) the cumulative

stereotyped behavior scores for each 15 min-interval; £) the
overnight spontaneous locomotor activity counts for each 2
hr-interval; 1) the APO-induced locomotor activity counts
for each 18 min-interval; and 4) the change in body temperature, were averaged and compared between SHR and the two
normotensive rat strains by Student's t-test.

Slopes of the

log-dose response curves obtained during the body temperature
experiments were compared by ANOVA linear regression.

RESULTS
A.

Blood Pressures
An e reva t-e-d-systo-1-1-c~b-l_o_o_d-pr-e-s-sure-tnat-wa:s-very-lTi-gh-Iy·----

significantly different from those of the normotensive strains
existed in the SHR used for the present study.
~ 1

strain the blood pressure averaged 202
mean~

standard error of the mean) (n

In this rat

mrnHg (arithmetic

= 157).

Systolic

blood pressures for the two normotensive rat strains averaged

135
(n

B.

+

=

1 mmHg for WKY (n = 157), and 131

~

1 mmHg for NWR

148).

Stereotyped Behavior
Two doses (O.j and 2.0 mg/kg) of APO were utilized for

the assessment of drug-induced stereotyped behavior in these
three rat strains.

It was found that a 2.0 mg/kg dose of APO

induced stereotyped behavior within a few minutes after injection
and that at this dose the stereotypy lasted for approximately
90 min.

Gnawing behavior without motor activity, which is the

most intense behavior, occurred mainly during the 15-30 min
interval, although gnawing with motor activity occurred
during the first 15 min after injection and also during the

30-45 min interval.

These results are illustrated in Figure 1.
48
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This figure also shows, except for a single difference in
significance during the 4th interval, that the six 15-min
intervals of cumulated stereotyped behavior scores did not
differ significantly over the 90 min.

SHR, however, appeared

to recover from the stereotypic effects of APO faster than
either WKY or NWR.

The smaller cumulated score during the

45-60 min interval in SHR illustrates this possibility.
Since the 2.0 mg/kg dose of APO may have been.a supramaximal dose required for the induction of gnawing, the
stereotypic effects of APO at a second dose of 0.5 mg/kg
were also

assessed~

This dose also induced stereotyped

behavior within minutes of administration, but the duration
of stereotypy was only about half as long, 45 min, as with
2.0 mg/kg APO.

The intensity of the behavior observed at

this lower dose was much less than that observed with the
2.0 mg/kg dose.

Occasional to continuous sniffing with

exploratory type activity were the most intense behaviors
induced by the 0.5 mg/kg dose of APO, and these behaviors
occurred within the first 15 min as illustrated by Figure
2.

The 15-min intervals of cumulated stereotyped behavior

scores again did not differ signifcantly between each of
the three rat strains.

It can also be seen that SHR again

appeared to display a quicker recovery from these effects
of APO than either WKY or NWR as no stereotyped behavior
was observed in SHR during the J0-45 min interval.
Total stereotyped behavior scoras covering the entire
45 min for the 0.5 mg/kg dose if APO, and the entire 90
min for the 2.0 mg/kg dose of APO show no significant dif-

--

----------

~~~~--

ference between the three rat strains as summarized in
Table II.

A significant difference may have been expected

as suggested by the more rapid recovery from stereotypy
by SHR.
·To determine whether each of the rat strains was as
susceptible to attenuation of the stereotyped behavior
induced by APO as the other two strains, a O.J mg/kg dose
of HAL was used to antagonize this stereotypy.
Figure

J~1s

dose of-HAL

As sho.wn in

antagonized-t-n-e-st-erE:m-typ-e-d-be·-;;;;-;---~~-~

havior induced by 2.0 mgjkg APO to approximately the same
degree in each of the three rat strains.

C.

Locomotor Activity
As rats are nocturnal animals, their spontaneous loco-

motor activity was assessed during the night while they
were most active.

Figure 4 graphically represents the over-

night locomotor activity counts obtained from each.of the
three rat strains when their locomotor activity counts are
divided into 2-hr intervals.

No significant differences

were found to exist between each of these three rat strains
with respect to their overnight spontaneous locomotor
activity.

It can also be seen from Figure 4 that the loco-

motor activity increased significantly after the lights
were turned off.

As the locomotor activity counts did not

differ significantly between the rat strains before the
lights went off, the sudden increase in locomotor activity
counts after the lights were turned off indicates that the
one week light-dark schedule of 800-2000 hr was successful.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ---- ----.-.-=-=-=--"--··"c=.·.- --- ----- ---- ---------------- .

Figure

1--Stereotyp~d

APO.

behavior induced by 2.0 mg/kg
(For n values see Table II.)

Key: CUM S B SCORES = Cumulated Stereotyped
Behavior Scores; Time Interval 1 - 0-15_ _ _ _ __
minutes after injection with APO;
2 = 15-JO min; J = J0-45 min; 4 = 45-60
min; 5 = 60-75 min; 6 = 75-90 min.

* = Significantly
CE.<0.05).

different from SHR
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TABLE II

Total Cumulated Stereotyped Behavior Scores

0.,2 mgLkg ·-

Dose A:Q6morphine
Total Time
N

Rat
Strain

~2 min
b

WKY

().8 -+ 2.8
7.8 -+ 2.9

SHR

J.J -+ 0.7

NWR

~2-~om/Vkg

20 min
2
J9.b -+ 2.8
44.9 -+ 2.4
5.1
)).8
.:!:.

Figure )--Antagonism of 2.0 mg/kg APO-induced stereotyped behavior by O.J mg/kg HAL. (SHR = 6
rats; WKY = 8 rats; NWR = 6 rats.)
Key: CUM S B SCORES = Cumulated Stereotyped
Behavior Scores; Time Interval 1 = 0-15
minutes after injection with APO (HAL
pretreatment time= JO min); 2 = 15-JO
min; J = J0-45 min; 4 = 45-60 min;
5 = 60-75 min; 6 = 75-90 min.
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The locomotor activity counts obtained after administration of APO were compared to the spontaneous locomotor
activity counts obtained after administration of vehicle
for each rat strain.
for SHR.

Figure .5 shows the results obtained

In this figure it can be seen that the locomotor

activity counts obtained after APO during the time interval
of 36-.54 min was significantly greater than the spontaneous
(vehicle-injected) locomotor activity counts of the same
time interval.

A significantly greater number of locomotor

activity counts during the time intervals of 36-.54 min and

.54-72 min was obtained after injection of.APO in WKY when
compared to locomotor activity counts of vehicle-injected
animals (Figure 6).

Although not significantly greater,

the locomotor activity counts obtained from APO-treated WKY
were much greater during the 18-36 min interval than those
obtained from vehicle-injected WKY.

The locomotor activity

counts obtained from APO-treated NWR were significantly
greater than the counts obtained from vehicle-injected NWR
during the time intervals of 18-36 min and 36-.54 min as
shown in Figure 7.
By subtracting the locomotor activity counts obtained
after vehicle-injection from those obtained after APO-injection (Figures .5-7) one can construct Figure 8 which illustrates the actual degree of locomotor stimulation due to APO.
This subtraction was done in order to determine the increase
in locomotor activity induced by APO which, if APO truly
induces locomotor activity, should be greater than normal,
or spontaneous, locomotor activity.

As can be seen from
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Figure 8, APO-induced locomotor activity did not significantly differ between the rat strains.

However, the induced

increase was much smaller in SHR than either WKY or NWR.
Even though the increase in locomotor activity was much smaller
in SHR than either WKY or NWR.

Even though the increase was

much smaller for each of the six 18-min intervals in SHR, the
total increase in locomotor activity counts for the entire
90 min was not significantly different between the three :,
stra~ns

D.

as summarized-in

Taol~III.

Body Temperature
Baseline rectal temperatures were not significantly

different between SHR, which displayed an average core temperature of )6.6

!_

0.1 °C (n

= 114),

and NWR, which showed

an average body temperature of ]6.7 + 0.1 °C (n

= 118).,

WKY displayed a baseline body temperature significantly lower
than either SHR or NWR as its rectal temperature averaged
36.2

!_

0.1 °C (n = 139).

The initial body temperature experiments performed
utilized an intraperitoneal dose of 2.0 mg/kg APO.

It was

discovered that the hypothermia produced by this dose of APO,
as shown in Figure 9, was of greater magnitude and more prolonged in SHR than in NWR.

The decrease in body temperature

was significantly greater in SHR during the entire duration
of the hypothermic response when compared to NWR.

WKY, on

the other hand, displayed a hypothermic response similar in
magnitude to that of SHR.

Return to baseline temperature

was faster, however, in WKY as there was a significant differ-

Figure 4--0vernight spontaneous locomotor activity.
Experiment begun at 1600 hr.
2000 hr.

Lights off at

(For n values see Figures 5, 6, and 7.)
Key: Time Interval 1 = 0-2 hours after injection with vehicle; 2 = 2-4 hr; J = 4-6
hr; 4 = 6-8 hr; 5 = 8-10 hr; 6 = 10~12
hr; 7 = 12-14 hr.
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TABLE III
Total activity induced by 2.0 mg/kg APO for 90 Min
Rat Strain ~nl

Total Counts

NWR ( 8)

1090.9 .:!:. .351. 0

WKY (6)

1194.7.:!:. 516.8

SHR (11)

4,35.0 .:!:. 292.4
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ence in the change in body temperature from 75 min to the end
of the hypothermic response when compared to SHR.
To determine whether this hypothermic effect was dependent on the stimulation of DA receptors, HAL at an intraperitoneal dose of O.J mg/kg was administered 30 min prior to
the APO challenge.

As illustrated in Figures 10 and 11, this

dose of HAL significantly attenuated the hypothermic response
in NWR and WKY.

This same dose of HAL also significantly

antagonized the hypothermia in SHR as illustrated in Figure
12.

However, the drop in body temperature produced in SHR

was still significantly greater than that produced in either
NWR or WKY (Figure 1)).

A dose of 0.5 mg/kg HAL was required

in SHR to attain the same degree of attenuation provided by
0.3 mg/kg HAL in NWR and WKY (Figures 12 and 1)).
Graphic representations similar to the one obtained from
the hypothermic response to 2.0 mg/kg APO were also obtained
from the hypothermic responses to 0.25 mg/kg, 0.35 mg/kg, and
0.50 mg/kg doses of APO.

These curves are shown in Figures

14, 15, and 16, respectively.

At each of these three doses

the magnitude and the duration of the hypothermic effect was
greater in SHR than NWR.

Only at the 0.5 mg/kg dose of APO

was the hypothermic response more prolonged in SHR than WKY.
Since these time-course curves of APO-induced hypotpermia
employed log-doses of APO, construction of log-dose response
curves from the results of these three doses was possible.
These log-dose response curves were constructed by plotting
the averages of the maximum decreases in body temperature
displayed by each rat.

Figure 17 shows the log-dose response
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curves obtained for each rat strain.

By use of linear re-

gression analysis it was determined that the slopes of the
curves equalled: 1) 2.54 for SHR; g) 2.22 for WKY; and 1) 1.70
for NWR.

These slopes were not significantly different as

determined by linear regression analysis.

Since the magni-

tude of the decrease in body temperature was significantly
greater in SHR in comparison to NWR for each of the three
doses of APO, it was calculated that APO appears to be approximately 1.78 times (95% confidence limits: 1.37 to 2.JO) more
potent in SHR than NWR.

Or, in other words, that SHR appears

to be approximately 1.78 times more sensitive to the hypothermic effect of APO than NWR.

Because all three of the average

maximum drops in body temperature for WKY did not differ significantly from either SHR or NWR, apparent potency of APO in
this strain was not calculated in comparison to either NWR or
SHR.
During these studies, it became apparent that different
doses of APO were required to elicit the same time-course of
hypothermia in the three rat strains.

Figure 18 shows that

a dose of 4.0 mg/kg was necessary to elicit the same hypothermic response in NWR as 2.0 mg/kg APO in WKY, and 0.5 mg/kg in
SHR.

These doses also appear to be threshold doses as 4.0

mg/kg caused the same drop in body temperature as 2.0 mg/kg
in WKY (Figure 19), and 0.5 mg/kg APO induced the same decrease
as 2.0 mg/kg APO in SHR (Figure 20).

Whereas the higher dose

was capable of prolonging the duration of the hypothermic
response in SHR, the hypothermic response to 4.0 mg/kg in

WKY was not significantly different from that elicited by a
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2.0 mg/kg APO.
To ensure that this difference in temperature response
was not a phenomenon specific to APO, a second dopaminergic
agonist, L-DOPA (coupled with pretreatment of the DOPA
decarboxylase inhibitor, carbidopa) was used.

It was assumed

that L-DOPA is metabolized to the neurotransmitter DA in
the brain.

Figures 21 to 23 illustrate the time-course of

the hypothermic response to three log-doses of L-DOPA.
These curves are strikingly similar to those obtained after
administration of APO in that the duration of the hypothermic
effect was greater in SHR than NWR.

In contrast to APO, the

hypothermic response was more prolonged in SHR than WKY at
25 mg/kg and 50 mg/kg L-DOPA.

A significantly greater

decrease in body temperature occurred at 25 mg/kg and 50 mg/kg
doses of L-DOPA in SHR than in WKY or NWR.

At a dose of 100

mg/kg L-DOPA the drop in body temperature was significantly
greater in SHR than NWR.

WKY at this dose of L-DOPA dis-

played a response somewhat intermediate to the other two
rat strains and thereby did not differ significantly from SHR.
Since log-doses of L-DOPA were used, it was again possible
to construct log-dose response curves of the average maximum
drop in body temperature per rat.

The L-DOPA log-dose re-

sponse curves, as shown in Figure 24, are very similar to
those obtained from APO.
equalled:
NWR.

1)

1.83 for SHR;

Slopes calculated for these curves
~)

2.18 for WKY; and 1) 1.99 for

These slopes were not significantly different from one

another.

The average maximum decreases in body temperature

induced by L-DOPA were significantly greater in SHR than in

..- - - - · - -

NWR at the high and low dose.

Since the points at the ends

of the curves differed significantly, the potency of L-DOPA
in SHR in comparison to NWR was calculated.

L-DOPA was found

to be approximately 1.78 times (95% confidence limits, 1.J4
to 2.35) more potent in producing hypothermia in SHR than
NWR.

Or, in other words, SHR appear to be approximately

1.78 times more.sensitive than NWR to the hypothermic effect
of L-DOPA.

As with the APO data, potency of L-DOPA in WKY

in comparison to SHR or NWR were not calculated as the
hypothermic responses were not significantly different
from either SHR or NWR.
Chronic lithium treatment did not significantly affect
the hypothermia caused by 0.5 mg/kg APO in either NWR or
WKY as illustrated in Figures 25 and 26, respectively.

Both

lithium- or sodium-treated NWR and WKY displayed a maximum
drop in body temperature of approximately 0.7 to 0.8 °C at
JO min.

Sodium-treated SHR, on the other hand, displayed

a maximum drop of about 1.3 °C at J0-45 min as illustrated
by Figure 27.

This figure also shows that lithium treatment

significantly attenuated the APO-induced hypothermic
response in SHR.

Instead of displaying a body temperature

drop of 1.3 °C as in sodium-treated SHR, the lithium-treated
animals displayed a drop of 0.7 °C at JO min in much the
same manner as sodium- or lithium-treated NWR and WKY.

There-

fore, as Figure 28 shows, lithium altered the hypothermic
response in SHR so that it was similar to those displayed
by NWR and WKY.

Lithium-treated NWR differed significantly

from lithium-treated SHR from 75-150 min.

However, this

75
difference occurred after the hypothermic response had
ended.
The effect that lithium may have had on body temperature
was roughly analyzed to ensure that it did not affect the
response to APO by altering baseline body temperature, particularly in SHR.

It was found that the baseline body tem-

peratures of sodium-treated rats averaged: 1) )6.5 ~ 0.1 °C
for SHR; £) )6.7 ~ 0.2 °C for WKY; and
NWR~L1thium-treated

2)

)6.4 ~ 0.1 °C for

rats demonstrated a lower baseTine

rectal temperature which was )6.1 ~ 0.2 °C for all three of
the rat strains.
Serum lithium levels were 0.0 mEq/1 in sodium-treated
rats, whereas in lithium-treated rats they were found to be:

1)

1. 05 + 0. 11 mEq/1 in SHR; 2) 1. 24 ~ 0. 08 mEq/1 in WKY; and

2) 1.01 + 0.05 mEq/1 in NWR.

Blood pressures were measured

on the 15th day (the day following cessation of chronic treatment) and were found not to be significantly changed in either
NWR or SHR (Table IV).

However, the blood pressures in SHR

were lower, though not significantly, after lithium treatment.

WKY blood pressures were not measured because of the

lack of .a significant change in the other normotensive strain.
Chronic treatment of SHR with hydralazine was found to
normalize their blood pressure.

The systolic blood pressure

of these animals averaged 1)7 + J mmHg.

Despite this nor-

malization of blood pressure, the hypothermia induced by 0.5
mg/kg APO was not significantly different from the hypothermic
response induced in untreated SHR (Figure 29).

Figure 9--Hypothermia induced by 2.0 mg/kg APO.
(SHR = 15 rats; v~Y = 25 rats; NWR = 24
rats.)

* = Significantly
(J2.<0.05).

**

~

different from SHR

Highly significantly different from
SHR ( £<0 • 01 ) .

*** = Very

highly significantly different
from (J2<0.001).
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Figure 10--Antagonism of 2.0 mg/kg APO-induced hypothermia (n = 24 by O.J mg/kg HAL (n = 9)
in NWR.
Key1 TEMP - Temperature

* = Significantly

different from rats injected only with APO (£<0.0.5).
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Very highly significantly different
from rats injected only with APO
(£<0.001).

FIGURE TEH .
0.5

c

H
A
H
G

0

1'"-'<
. ~-

e

E

I
N

·-"¥"···-~..
.

***

0

2.0 APO

X

O.J HAL/2.0 APO

,:_•••........
J<.••.c·~~
L.~
:
.
~..•••

•''~-----~·-···¥
·l......
*** . *** . ***

***

~

.

~· .

*

-0.5

B
0

0
y

-1.0

T

E
p

M

-1.5

•r...,
2 9
- · _, 1
e

1 1 1 1

I

2s

1 1 1 1

I

59

1 1 1 1

I

75

1 1 1 1

I

1 1 1 1

100

I

1

12s

1

1

1

1
15e

--.J

\.()

TIME <MIH)
n•,-

,.,..,r·-""lii"-"'11"'!"TI"'1

F'igure :1.1--Antagonism of 2. 0 mg/kg APO-induced hypothermia (n = 25) by O.J mg/kg HAL (n =. 9)
in WKY.
Key:

~'ENIP

= Temperature

** = Highly

significantly different from
rats injected only with APO (:p_<0.01).

*** = Very

highly significantly different
from rats injected only with APO
{:p_<O. 001) •

FIGURE ELEUEH
I

0 2.0 APO

0.5-y-

c

X

I

O.J HAL/2. 0 APO

H
A

N

0.0

G

E
I

H

I

\

---

***

-9.5

B

0
0

'f

-1.9

T
E
M
p

-1.5

•r.,

-

2 8
· --'

1

a

1 1 ,

1

I25

1 1 , 1

I50

1 1 1 1

I75

TIME (MIN>

I
100

1 a 1 1.

1 • • 1

I

I

12~;

1 1 1 •

J
150

co
.....

-----~--~------·---

-··-··--·-

····-·

--

Figure 12--An.tagonism of 2.0 mg/kg APO-induced hypothermia (n = 15) by 0.3 mg/kg (n = 9) and
0.5 mg/kg (n = 9) HAL in SHR.
Key: TEMP

= Temperature

* = Significantly

different from rats
injected only with APO (:Q.<0.05).

** = Highly

significantly different from
rats injected only with .Are (J?.<O. 01).

*** = Very

highly significantly different
from rats injected only with APO
(J?_<0.001).

FIGURE TWELVE
0 2.0 APO
,...
H
A
H
G
c...

a.s

***

IJ

I
N

8
0
0
'I

T ,.,-·

***

*** ,.JII'
,

•,. T
j.·"
• ~--

0.0

·..

''
\

-0.5

•

***
_l

***
T

f'

,
,
,•,- ***

***
.l

. ***
-·-"'----~-;.-.,__.,~!.i---

..);f····· -.----~---J: ··~

.x··
-.~:

...

***
T

.,,r•l•
***

***

*<t*

·-.I***
..I_
I

.

O.J HAL/2.0 APO
A0.5 HA~2.0 APO

*
l

.............

T·····~·~.
.
1 ••.

***

***

.
**

X

* . •

II

'j-----¥·

***

-1.0

T

!="

M

?

-1.5

or.,

2 0
- . ~f

e

I

I

I

.I ·t
25

I

I

I

i

I

se

i

I

I

I

I

75

TIME <MIH>

I

i

I

I

I

100

I

I

i

I

I

I

I

12sl

I

i

i.

I

1se

co

\...)

Figure 13--Change in body temperature induced by
2.0 mg/kg APO after pretreatment with
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decreases in body temperature produced
by APO. (For n values see Figures 14,
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Figure 22--Hypothermia induced by 50 mg/kg carbidopa +
50 mg/kg L-DOPA. (SHR = 8 rats; WKY = 7
rats; NWR = 9 rats.)
- Temperature.

* = Significantly
(:Q.< 0 • 0 5 ) .

**

~

different from SHR

Highly significantly different from
SHR (:Q<O. 01).

*** = Very

highly significantly different
from SHR (£<0.001).

FIGURE TWENTY-TWO
0.5

...

~

**

~

.Ji..._j-r

,,~rr

A
~I

0.0

G

*

*

E

I
H

**

,-

-0.5

,,' 1
,' **

B
0
D

/,·~,
,-·

*

'(

-1.0

••

~

p

/

**

·-¥ .
' ·,

.....T
0

oHWR
XWKY
ASHR

-1.5

..r. .

I

.~--t

1

..i'

f""''

I

.

,
,/
./
,,.II!
.If"
·l

,/
./

r·-·t

,...
J

-2.0

- _j
Il--l~,~

e

se

25

75

100

1251

I

~

0

150

'u)

TIME <MIN>
.I

I

I

I

:1

I

I'

I :,JJI

:1:

:rmn::r~rm:rm :nr:rll~llf:

rcn,

rnT::1:JL·:r

:.r:.-

1·, :

: ·1

1r..p;:~:::

~-n:;~rrn:iiJL: :::~mJt:•rn~

. :::T::::r~:-m: .r::1

Figure 23--Hypothermia induced by 50 mg/kg carbidopa +
100 mg/kg L-DOPA. (n = 8 rats for each rat
strain.)
Key: TEMP

= Temperature.

* = Significantly

different from SHR

(:Q<0.05).

** = Highly

significantly different from
SHR (:Q<O. 01) •

*** = Very

highly significantly different
from SHR (£<0.001).

10.5

w

If)

w

N

0:::
:X:

.......
I

>.......

:z:
w
3:

t-

LLJ
~

::;:)

I

-

-

I

1
M
I

(\J

I

u

LL.

o~~z~w

-z

oooar

~WE~

u
0

,,tl

,,

r_;

Figure 24--Log-dose response curves to carbidopa +
L-DOPA-induced hypothermia. {F'o·r n values
see Figures 21, 22, and 2J.)
Key: MAX DROP IN B. T.
Body Temperature.

* = Significantly

= Maximt~

Drop in

different from SHR

(:Q<O. 05).

*** = Very

highly significantly different
from SHR (:Q<0.001).

107

~

>-

(J)

:::!!:

::s::

~

~

:X

:z:

ox~

. ~., \*

~
.

'.

\

'\ '\

.. .'

--------------------------~~--~.---,.--------------------------------

\

\

\

..-4

\

\

\

.'

"\ '\

\ \

..-4

.

"\ '\
'
\\

~
\\

·.

0:

..-4

_,I

,.'
'•

UJ

(/)

\

..-4

''• '\
'\ '\

.

'\\
'\ '\
''. '\
'\ '\
' ' *
t-k~:

0

~

I

t-

..-4

-

lJJ
0::::
~

u

LL.

M

I

' I

(S)

&f')

N

..-4

..-4

0

c
I
'-='
0
.....1

LL

•
>t::z:
w

0

c

' '
•..\ •

~
~

. a..

(S)

-

-

F

f

Figure 25--Hypothermia induced by 0.5 mg/kg APO after
chronic treatment with sodium or lithium in

NWR.

Key: NA TX =Sodium-Treated (n = 8);
LI TX =Lithium-Treated (n = 8);
TEMP = Temperature.

*

= Significantly different from lithiumtreated rats (£<0.05).

109

XX

t- 1-

UJ

:::>

.....

LL.

I

>t-

:z:

w

:X

t-

LLJ

~
::;)

lf)

cs:>

C!;)

(S)

~

.....

LL.
u~~z~w

-z

oooor

~WE~

u
0

-~-----~-~------

-------

Figure 26--Hypothermia induced by 0 . .5 mg/kg APO after
chronic treatment with sodium or lithium in

WKY.

~----------------------~K~~~A-TX-=-~~d~um-Treat~d-\n-=-!~)n;----------------~

LI TX =Lithium-Treated (n = 10);
TEMP = Temperature.

111

XX

t- t-

<t:-

:z:

...I

ox

cg

~--~--~~--------11:~
'
~

N
~

•
''
'
~
''•
'

~

"

~

'\

x......

,

-:z:

...

1:::

&f)

N

X

U)

I

>t-

:z:
w

3:

t-

w

~
~

L!J

l()

CS)

lf')

rS)

(S)

CS)

-'

I

......

IJ..
0

Figure

by 0.5 mg/kg APO after
chronic treatment with sodium or lithium in
SHR.

27--H~~othermia.induced

Key: NA TX = Sodium-Treated (n = 9);
I,I TX = Lithium-Treated (n = 9);
TEMP = Temperature.

* = Significantly

different from lithiumtreated rats (E<0.05).

** = Highly

significantly different from
lithium-treated rats (£<0.01).

*** = Very

highly significantly different
from lithium-treated rats (£<0.001).

FIGURE TWEHTY-SEUEH
oNA TX
XLI TX

0.5

c

H.
A

H
G

E

a.e

I
H
B

0

-0.5

0

y

.*. ..J<-·---1-···-*-.J·-·*·····-*

\\*

. .*
..........

~

__ ,

,-

T~ ,--

,-~---:j('

•'

T

E
~

-1.0

•c
-1.5

r••••l••••l••••l••••l••••j••••l
0
25
50
75
100
1 .5
150
TIME <MIH >

......

......

'I...)

Figure 28--Hypothermia induced by 0.5 mg/kg APO after
chronic treatment with lithium. (For n
values see Figures 25, 26, and 27.)
Key: TEMP - Temperature.

* = Significantly
(]2<0.05).

different from SHR

FIGURE TWENTY-EIGHT
0.5

*

c

*

H
A
H

*

G
E

1

~

.* .l..-l....l...l.~---···*

e.e

/ ;::-t-·1-.. .t·f-t-·1

H
B
0

,' If

,l ,/' l

0
y

T
E
M
p

0 N~lR
XWKY
A SHR

,- ~ ,/

-0.5
.,.~'
_,~~·
.

_..::,:'1/

~

,-

oc
0
-l . _, I
e

I

I

I

I

I
25

I

I

I

I

I'
5e

I

I

I

I

75

TIME <MIN>

f

I

I

I

I
100

I

I

I

I

H
I

12~)

I

f

I

I
1se

......

......
'-"

···-------------

---- - - - - - - - · - - - - - - - · · · · ·

-----~

116

TABLE IV
Blood Pressures Before and After Sodium
~r~Li thrUITlT-rea tment
Rat
Strain
{n}
NWR

( 8)

SHR

( 9)

Treatment

Blood Pressures
Before
After
{mmHg}
{mmHg}

Na.

134

+

2

144

+

6

Li

134

~

3

135

~

4

Na

198

-+

1

214

+

8

Li

203

+

2

190

~

10

-----------------------------------

Figure 29--Effect of chronic hydralazine treatment
on hypothennia induced by 0.5 mg/kg APO
in SHR.
Key:

:ttrn-~J\: ==

Hydralazine-,r-r-eated (n
NON TX = Non-Treated (n = 9);
TEMP = Temperature.
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DISCUSSION
Results of the present study agree and disagree with
several of those reported for earlier studies.

The stereo-

typed behavior results, in particular, agree with those reported by Shimamoto and Nagaoka (1972) thereby confirming the
lack of difference in APO-induced stereotyped behavior between
SHR and normotensive rat strains.

SHR showed a spontaneous

locomotor activity immediately after handling and placement
into the test cage which was not significantly different from
that of either WKY or NWR.

These results conflict with the

results obtained by other investigators (Shimamoto and Nagaoka, 1972; Pappas et al., 1974; Rosecrans and Adams, 1976;
Myers et al., 1977).

However, the present study appears to

be the first on the effect that a direct-acting DA agonist has
on locomotor activity of SHR.

Additionally, this is also the

first study on the effect that APO has on the body temperature
of SHR.

These latter experiments have given further insight

into the possible alterations of hypothalamic function of
SHR.

Therefore the objectives set down for this study have

been met as to determining the possible alterations in DA receptor sensitivity in SHR in the:

1) corpus striatum;

limbic forebrain; and 1) hypothlalmus.
119

~)

meso-

. 120
No significant difference in APO-induced stereotyped
behavior was found to exist between the three rat strains
either in onset, intensity, or duration.

If SHR do possess

supersensitive striatal DA receptors, then the gnawing
behavior would have been more prolonged at 2.0 mg/kg APO
than in the two normotensive rat strains.

Furthermore, the

intensity of behavior displayed at 0.5 mg/kg APO would
probably have been greater in SHR.

Instead, the duration of

stereotyped behavior appeared to be slightly shorter in SHR
which could possibly be suggestive of subsensitive striatal
DA receptors.

However, the intensity of stereotypy observed

in each of the three strains was not significantly different
from one another at either dose of APO.

Therefore there

appears to be no alteration in striatal DA receptor sensitivity in SHR.
The low intensity component of APO-induced stereotyped
behavior is present upon return to normal behavior and this
lower intensity of behavior is apparently mediated via the
mesolimbic forebrain (Costall et al., 1975).

This brain

re~

gion is also apparently responsible for mediation of locomotor
activity (Jackson et al., 1975; Costall and Naylor, 1976a).
Serotonergic neuronal systems also apparently have an inhibitory effect on these mesolimbic dopaminergic neurons which
mediate iocomotor activity (Costall et al., 1976b) and may
possibly have an inhibitory effect on the low intensity component of APO-induced stereotyped behavior since it has
locomotor activity incorporated into it.

As APO has been

suggested to activate central serotonin neurons and thereby
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attenuate its own stimulatory effect on locomotor activity
(Grabowska et al., 197.3a), it may be possible that the
slightly faster return to normal behavior demonstrated by
SHR is the result of stimulation by APO of the hypothesized
(Rosecrans and Adams, 1976) hyperfunctional central serotonergic neuronal systems present in SHR.
APO was able to significantly increase locomotor activity
in WKY and NWR for at least .36 min of the total 90 min, whereas in SHR APO increased locomotor activity for only 18 min
of the entire 90 min.

In addition, APO-induced locomotor acti-

vity was much less, although not significantly, in SHR than
either WKY or NWR.

A possible explanation for such results

is similar to the one suggested for the faster return to normal behavior from stereotyped behavior.

Since central sero-

tonergic neuronal systems apparently inhibit the mesolimbic
dopaminergic neuronal systems responsible for induction of
locomotor activity (Costall et al., 1976b), and APO appears
to stimulate these inhibitory neuronal systems (Grabowska et
al., 197Ja), then the possible stimulation of the hypothesized
(Rosecrans and Adams, 1976) hyperfunctional serotonergic systems in SHR may attenuate the locomotor stimulatory effects
of APO.
Both the stereotyped behavior and locomotor activity
results obtained in the present study need further confirmation.

This could probably be best determined by direct appli-

cation of direct-acting dopaminergic agonists, including DA
itself, to the corpus striatum and mesolimbic forebrain.
This would, of course, require the implantation of bilateral

122
cannulae into the caudate nucleus and nucleus accumbens.
Comparison of the responses elicited in SHR to those elicited
in WKY and NWR, as in the present study, would supply further information as to the sensitivity of the DA receptors
in these areas of the brain in SHR.
Spontaneous locomotor activity did not differ significantly between the three rat strains.

These results disagree

with those of earlier studies which have indicated a greater
spontaneous

ocomotor activity in SHR (Snimamoto and Nagaoka,

1972; Pappas et al., -1974; Myers et al., 1977), and a lesser
spontaneous locomotor activity in SHR (Rosecrans and Adams,
1976).

These differences in results may be due to differences

in experimental design.

Whereas the present study was inter-

ested in locomotor activity, several of the earlier studies
were interested in open field behavior as well as locomotor
activity.

Therefore in these earlier studies the animals had

not been previously acclimated to their test cage or enclosure,
whereas in the present study the animals had been acclimated
to their test cage prior to commencement of the experiment.
It may be possible that SHR will show greater exploratory
activity and thus locomotor activity upon placement into
strange surroundings than normotensive control animals.

This

increase in exploratory behavior and thus activity may be due
to the animal's reaction to a new environment.

Measuring an

animal's reaction to new surroundings is the purpose of the
open field test.

Therefore these investigations may have mea-

sured "reactivity" whereas the present study, since the animals had already undergone their reaction to the environment,
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In contrast, Rosecrans and Adams (1976) found activity
to be less in SHR than normotensive rats upon placement into
a strange environment.

Upon repeated exposure to the test

environment the activity of the normotensive control strain
decreased dramatically while that of SHR changed very little.
As a result, the locomotor activity of SHR subsequently became
greater than that of the normotensive animals.

This inves-

tigation apparently also measured reactivity rather than
act1v1ty.

It appears that the

resu~ts ootained~n

tne present

study cannot be reconciled with those of the previously
reported studies since the locomotor activity of SHR did
not differ from either of the normotensive control rat strains
utilized in this

stud~.

However, it seems that the earlier

studies measured reactivity whereas the present study measured
locomotor activity •
. Furthermore, overnight spontaneous locomotor activity
did not differ between SHR and the normotensive control strains.
This would seem to provide further evidence that spontaneous
activity does not differ between SHR and normotensive animals,
especially when it is taken into consideration that rats are
nocturnal creatures.

In addition, if mesolimbic DA receptors

of SHR were supersensitive or subsensitive, then compensatory
mechanisms have occurred so that spontaneous locomotor activity remains similar to that of normotensive animals.

Super-

sensitive mesolimbic DA receptors in SHR, however, are probably unlikely due to the smaller increase in locomotor activity induced by APO in SHR than WKY or NWR.

The possibility

of subsensitive mesolimbic DA receptors is at present diffi-
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cult to eliminate and must await further investigations.
APO elicited a significantly greater fall in body temperature in SHR than NWR while the response elicited from
WKY was intermediate to the other two rat strains at all doses
used.

As a result, the log-dose response curves obtained

from the maximum drop in body temperature for the three rat
strains were parallel to one another.

Because of the signi-

ficant difference between SHR and NWR, it was determined that

SHR than NWR.

This apparent greater potency of APO could be

due to one of several reasons.

These reasons could also be

used to explain why a larger dose of HAL was required in
order to attenuate the hypothermic response in SHR to the
same degree as in WKY and NWR.
The first explanation is ·that SHR may metabolize APO at
a slower rate than WKY or NWR which would thus allow APO to
act for a longer period of time on the DA receptors.

A slower

rate of metabolic degradation of APO would not be inconsistent
with the finding that ethanol is metabolized at a slower rate
in naive SHR than naive NWR (Israel et al., 1977).

It is

known that approximately 80 percent of APO is conjugated with
glucuronide in rat liver and then excreted in the urine (Kaul
et al., 1961a, 1961b).

The other 20 percent is apparently

metabolized by both liver and brain catechol-0-methyl
transferase (COMT) (McKenzie and White, 1973).

Since the

liver is the major site for the metabolic degradation of APO,
alterations of liver metabolic enzymes in SHR could increase
the sensitivity of this rat strain to APO.

However, several
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earlier studies have found that this is not the case.

Pento-

barbital sleeping time was found to be significantly shorter
in SHR than WKY which was suggested to be the result of a
faster rate of metabolic degradation of pentobarbital in SHR
(Willis and Queener, 1977).

In a separate study it was found

that the hexobarbital sleeping time, in vitro activities of
microsomal enzymes, and the concentration of cytochrome P-450
in SHR did not differ significantly from those of NWR (Vain-

tent with the concept of a slower rate of metabolic degradation of APO in SHR.

In addition, if the rate of metabolic

degradation of APO were slower in SHR, then the intensity and
duration of APO-induced stereotyped behavior, and the duration
of APO-induced locomotor activity should have been greater in
SHR than in WKY and NWR rather than smaller as observed in
the present study.

It may be possible, however, that the

greater amount of APO present due to its slower rate of breakdown and removal would allow stimulation of the hyperfunctional serotonergic system in SHR (Rosecrans and Adams, 1976)
thereby causing these APO-induced responses to inhibit and
attenuate themselves.

However, the alteration of the hypo-

thermic response in SHR by chronic lithium treatment would
be difficult to account for by this hypothesis (as will be
discussed later).
It could also be suggested that there may be an alteration in COMT activity in SHR which would have to be localized
to the hypothalamus.

However, it again would be difficult to

explain the results obtained from the SHR chronically treated

126
with lithium (as will be discussed later).
A second explanation for the observed difference in the
hypothermic response is that there may be an enhanced
distribution of APO to the brain of SHR.

If this were the

case, however, then APO-induced stereotyped behavior and
locomotor activity would also have been significantly greater
in SHR.

This lack of difference is not surprising consid-

ering that APO is highly lipid-soluble and easily permeates
1 e--'ol-m::rd=hra±n=b-arrre-r~(-B -D-B)~.~T-rr-e-ref ore
r---~~~--r-~,h
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difference would be expected between the normotensive strains
and SHR.

This would be so even if there were a more permeable

B-B-B present in SHR as suggested by Tanaka et al. ( 1972).
As a result, any enhanced distribution of APO in SHR would
have to be to the site of the hypothermic response which has
been shown to reside within the preoptic anterior hypothalamus (Cox and Lee, 1977a, 1977b).
APO has been shown to have a distribution to the hypothalamus which is less than to the rest of the brain (Butterworth and Barbeau, 1974).

An alteration within the brain of

SHR which would allow a greater amount of APO to reach the
hypothalamus could account for the increased sensitivity of
this unique rat strain to the hypothermic effect of APO.

This

alteration would also have to alloW enhanced distribution to
the hypothalamus of very lipid-insoluble compounds.

SHR was

found to be more sensitive than normotensive strains to the
hypothermic effect of L-DOPA, a highly lipid-insoluble molecule, in a manner similar to the way this strain was more sensitive to APO.

Additionally, chronic lithium treatment would
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have to be able to correct this alteration as lithium treatment changed the APO-induced hypothermic response to one
similar to that shown by the normotensive strains.

It seems,

by this hypothesis, that lithium would also have to alter the
distribution of' APO to various regions in order to correct the
original dysfunction in distribution.

Such an alteration in

SHR which.can increase the distribution of both lipid-soluble
and lipid-insoluble molecules to the hypothalamus, and which
can be corrected by a positively-charged ion does not seem
plausible.

Therefore the possibility that a dysfunction exists

within SHR brain that increases the distribution of APO to
the hypothalamus can be eliminated.
L-DOPA, as previously mentioned, was also found to
cause hypothermia in much the same manner as APO.

This seems

to be clearly illustrated by the similarities in the log-dose
response

curv~s.

Similarly to APO, L-DOPA also appeared to

be approximately 1.78 times more potent in producing hypothermia in SHR than NWR.

These results would seem to suggest

that the difference in the hypothermic response between SHR
and NWR is not a phenomenon strictly reserved to APO.

This

would also argue against the first two explanations for the
observed results; that is, that there may be an alteration
of metabolic degradation of APO or that there may be an
enhanced distribution of APO to the hypothalamus in SHR.
On the other hand, these results would seem to indicate that
in SHR there is some sort of postsynaptic alteration of the
DA receptors responsible for mediating the hypothermic response.
However, the mechanism of action of L-DOPA depends on pre-
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synaptic events as well as on postsynaptic events whereas
the responses observed from APO, at the doses used, should
have been the result of postsynaptic actions.

Since the

L-DOPA log-dose response curve of SHR was parallel to the
log-dose response curve of NWR it may be assumed that the
mechanism of hypothermia was identical in the two strains.
Also, the APO log-dose response curves were parallel which
would again suggest the same mechanism of action.

Since the

APO-induced hypothermic response depended on a postsynaptic
site of action, it could be assumed that the presynaptic
events in response to L-DOPA were the same in the two rat
strains.

Therefore it can be argued that the difference in

the hypothermic response to L-DOPA between the two strains
was also the result of postsynaptic alterations in SHR.
It might also be argued that L-DOPA displaced serotonin
from serotonergic neurons thereby leading to the hypothermic
response (Maj and Pawlowski, 197.3; Reichenburg and Vetulani,

197.3) and that APO indirectly stimulated the release of serotonin from neurons which participate in the hypothermic response (Grabowska, 1974; Przewlocki, 1976).

As SHR have been

hypothesized to possess hyperfunctional serotonergic systems
(Rosecrans and Adams, 1976), stimulation of the serotonergic
neurons involved in the mediation of hypothermia by either
L-DOPA or APO may have led to the significantly greater fall
in rectal temperature.

However, the dose of L-DOPA used in

the present study (25 mg/kg to 100 mg/kg) was smaller than
those used in an earlier study (100 mg/kg and above (Maj and
Pawlowski, 197.3)).

Another study used intraventricularly-
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administered L-DOPA (Reichenburg and Vetulani, 197J).

Both

of these studies reported that the DA antagonists, pimozide
and spiroperidol, were unable to attenuate the L-DOPA-induced
hypothermia.

In contradiction to these earlier investigations,

it was observed during the course of the present study that
HAL could significantly attenuate L-DOPA-induced hypothermia
in SHR and NWR (personal observation).

It may be that large

amounts of L-DOPA are able to displace serotonin from serotonerg1c neurons.

ing response may be able to mask

the responses resulting from DA receptor stimulation.

Responses

from lower amounts of L-DOPA may be the result of the conversion of L-DOPA to DA and the subsequent stimulation of DA receptors.

HAL also significantly attenuated APO-induced hypo-

thermia.

Therefore the data obtained from the present study

appear to indicate that the stimulation of DA receptors was
responsible for the hypothermic response to

L~DOPA

and APO.

As a result, it seems that the L-DOPA- and APO-induced hypothermia observed in the present study was not due, either
directly or indirectly, to the release of serotonin.
Additionally, the results obtained from lithium-treated
animals would not support the hypothesis that a serotonergic
mechansim is the major contribution to the greater fall in
body temperature induced by APO in SHR.

Lithium has been

found to interact with some of the serotonergi,c neuronal
systems.

Thus lithium has been found to decrease the amount

of serotonin synthesized from L~tryptophan (Collard and
Roberts, 1975).

These results may be related to the observa-

tion that chronic lithium treatment can reduce brainstem sero-
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tonin levels by approximately 26 percent (Ho et al., 1970).
This decrease in brainstem serotonin could also be used as
an explanation for the attenuation by lithium of the APO-induced hypothermia in SHR as it has been shown that it is
brainstem serotonergic systems that participate in APO-induced
hypothermia (Grabowska, 1974; Przewlocki, 1976).

However, it

seems reasonable that such a decrease in brainstem serotonin
levels would also have occurred in the normotensive rat
stra1ns.

Therefore it seems plausible that chronic lithium

treatment would also have attenuated APO-induced hypothermia
in WKY and NWR.
A third explanation is that in SHR there are postsynaptic
alterations of the DA receptors in the hypothalamus which are
responsible for mediating the drop in body temperature.

This

alteration in the hypothalamic DA receptor results in the
greater sensitivity of SHR to the hypothermic effect of APO
and L-DOPA.

It was recently discovered that lithium has the

ability to "stabilize" DA receptor sensitivity.

This was

accomplished by showing that concurrent lithium treatment
could attenuate the increased response to APO-induced stereotyped behavior and locomotor activity observed when DA receptors are made supersensitive by chronic neuroleptic
treatment (Gallager et al., 1978; Pert et al., 1978).

"Sta-

bilize", as used by these authors, means that the lithium was
able to return the sensitivity of the DA receptor to normal.
Similar results were observed in the present study, except
that the DA receptors are apparently already supersensitive
in SHR.

As a result, lithium was found to alter the APO-in-
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duced hypothermic response of SHR to that shown by WKY and
NWR, just as lithium was able to alter the APO-induced behavioral responses of chronically neuroleptic-treated rats to
that of untreated rats.

Therefore it is suggested that the

DA receptors of the hypothalamus responsible for mediating
hypothermia are supersensitive in SHR.
This supersensitivity may be due, according to Pert et
al. (1978), toa
~------~oT-£)

1)

an increase in the number of DA receptors;

an increase in the sensitiv1ty of the existing DA re-

ceptors.

Pert and coworkers (1978) found that lithium could

prevent the increase in DA receptor binding sites induced by
haloperidol.

These results support their suggestion that li-

thium prevents the development of supersensitive DA receptors
by inhibiting the increase in the number of DA receptors.

On

the other hand, Stefanini and coworkers (1978) found that lithium could inhibit the stimulatory effects of DA on DA-sensitive adenylate cyclase.

They also found that lithium at

brain concentrations above those required for therapeutic
effect could inhibit basal activity of DA-sensitive adenylate
cyclase.

From these results it could be suggested that lithium

prevents the development of supersensitive DA receptors by
inhibiting the sensitivity of the existing DA receptors.
Therefore, with the data available at the present time, it
cannot be determined whether the proposed hypothalamic DA
receptor supersensitivity in SHR is due to:

1) an increase in

the number of DA receptors; or .f.) an increase in the sensitivity
of existing DA receptors.
Chronic hydralazine treatment was found to have no effect
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· on APO-induced hypothermia in SHR despite being able to normalize systolic blood pressure.

These results would seem to

eliminate any possibility that the difference in the hypothermic response between SHR and NWR was the result of peripheral vasodilating effects.

That is, it would seem unlike-

ly that greater vasodilation in SHR, and therefore dissipation of heat from SHR, was the cause of the greater fall in
rectal temperature produced by APO.

This is because hydrala-

zine is a smooth muscle relaxant and had already dilated the
vasculature of SHR as evidenced by the normal systolic blood
pressure.

As lithium was observed to slightly decrease blood

pressure in SHR, it could have been suggested that the alteration of the hypothermic response to APO in SHR by lithium was
due to this decrease in blood pressure.

Therefore, if the

greater hypothermia induced by APO in SHR was the result of
greater vasodilation, then hydralazine would have been able
to alter the APO-induced hypothermia in the same manner as
lithium was able to alter the hypothermic response.

Since this

response was not the same after chronic treatment with hydralazine or lithium, and hydralazine exerts its effect on the periphery, this suggests that lithium affected APO-induced hypothermia via a central mechanism of action.

Therefore it ap-

pears that the lack of significant effect on APO-induced hypothermia in SHR by hydralazine supports the suggestion that
the hypothalamic DA receptors responsible for mediating hypothermia are supersensitive in SHR.
The hypothermic responses obtained from WKY are more difficult to explain in that their responses were intermediate
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to those of SHR and NWR.

These results are similar to bio-

chemical studies in which significant differences between SHR
and NWR a+e lost when SHR are compared to WKY (Sjoerdsma,
1972; Yamabe et al., 197.3; Osumi et al., 1974).

Such obser-

vations have led to the controversy as to whether WKY or NWR
is the proper control strain for comparison to SHR.

It has

been suggested that WKY may possess hypertensive traits (Sjoerdsma, 1972), and therefore the similarity in response of WKY
to SHR may not be critical.

However, the hypothermic re-

sponse to APO of lithium-treated WKY was not significantly
different from the hypothermic response produced by APO in
sodium-treated animals.

These results suggest that no differ-

ence exists between WKY and NWR as the APO-induced hypothermia
was not affected by chronic lithium treatment in either rat
strain, but that there is a difference between WKY and SHR as
the hypothermic response elicited in SHR was altered by
chronic lithium treatment.
It appears that the most plausible explanation for the
results of the present study is that the hypothalamic DA
receptors responsible for mediating hypothermia are supersensitive in SHR.

This proposed alteration in hypothalamic

function is consistent with previous studies which have also
reported alterations in various hypothalamic functions in SHR.
Thus Bunag and coworkers (1975) hypothesized that the posterior hypothalamic pressor areas of SHR are hypersensitive.
These pressor areas have recently been related to hyperactivity of the sympathetic nervous system (Juskevich et al.,
1978; Takeda and Bunag, 1978).

Schmid et al. (1978) discovered

that cAMP levels are lower in SHR than WKY which was suggested by these authors to indicate a possible alteration of
the adenylate cyclase-cAMP-phosphodiesterase system in hypothalamic structures of SHR.

By observing elevated basal pro-

lactin release and normal suppression of prolactin release
in SHR, Sowers and coworkers (1979) hypothesized that hypothalamic DA metabolism is defective in SHR.

Thus the results

of the present study appear to be in agreement with other
studies that have postulated alterations of normal hypothalamic functions in SHR.
The conclusions of the present study obviously requires
further experimentation and verification.

There are a number

of procedures which might be employed in an effort to confirm
this hypothesis of SHR hypothalamic DA receptor supersensitivity.

Regional activity of DA-dependent adenylate cyclase

could give an indication as to the sensitivity of the hypothalamic DA receptor in SHR.

Additionally, regional DA re-

ceptor binding studies may also be helpful.

Furthermore, it

would be interesting to determine if there is a common denominator between the greater sensitivity of SHR to the hypothermic effect of APO and L-DOPA, and their greater sensitivity
to the inhibitory effect of L-DOPA on sympathetic nerve activity (Judy et al., 1978).

This may give a clue as to whether

or not the postulated supersensitive DA receptors are related
to the pathogenesis of hypertension in SHR.

Studies such as

these will be required to confirm the suggestion that the
hypothalamic DA receptors responsible for mediating hypothermia are supersensitive in SHR.

CONCLUSIONS
1.

There was no significant difference in stereotyped behavior induced by the direct-acting DA agonist APO between SHR and two normotensive control strains, WKY and
NWR, suggesting that there is no alteration in the sensitivity of DA receptors in the corpus striatum of SHR.

2.

There was no significant difference in locomotor activity, either spontaneous or induced by APO, between SHR,

. WKY, and NWR, suggesting that there is no alteration in
the sensitivity of DA receptors in the mesolimbic forebrain of SHR.
Ja.

SHR demonstrated a significantly pronounced and prolonged
hypothermic response to APO and L-DOPA than NWR.

b.

WKY displayed a response intermediate to SHR and NWR;
this may be due to the possession of hypertensive traits
by WKY.

c.

Lithium significantly attenuated APO-induced hypothermia
in SHR, and altered it to a response similar to WKY and
NWR.

d.

Since lithium has the ability to "stabilize" supersensitive DA receptors, and APO-induced hypothermia in SHR,
it is suggested that DA receptors in the hypothalamus
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responsible for mediating hypothermia are supersensitive in SHR.
of:

1)

This supersensitivity may be the result

an increase in the number of DA receptors; or

2) an increase in the sensitivity of the existing DA
receptors.
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